US20060010509A1 - Methods and compositions for producing germ cells from bone marrow derived germline stem cells - Google Patents
Methods and compositions for producing germ cells from bone marrow derived germline stem cells Download PDFInfo
- Publication number
- US20060010509A1 US20060010509A1 US11/131,153 US13115305A US2006010509A1 US 20060010509 A1 US20060010509 A1 US 20060010509A1 US 13115305 A US13115305 A US 13115305A US 2006010509 A1 US2006010509 A1 US 2006010509A1
- Authority
- US
- United States
- Prior art keywords
- cell
- bone marrow
- cells
- germline stem
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 322
- 238000000034 method Methods 0.000 title claims abstract description 177
- 210000001368 germline stem cell Anatomy 0.000 title claims abstract description 118
- 239000000203 mixture Substances 0.000 title claims description 45
- 210000004602 germ cell Anatomy 0.000 title description 71
- 210000004027 cell Anatomy 0.000 claims description 268
- 210000000130 stem cell Anatomy 0.000 claims description 198
- 210000000287 oocyte Anatomy 0.000 claims description 168
- 239000003795 chemical substances by application Substances 0.000 claims description 153
- 210000003631 female germ line stem cell Anatomy 0.000 claims description 141
- 108090000623 proteins and genes Proteins 0.000 claims description 86
- 210000001672 ovary Anatomy 0.000 claims description 73
- 210000001519 tissue Anatomy 0.000 claims description 60
- 230000004083 survival effect Effects 0.000 claims description 50
- 230000002611 ovarian Effects 0.000 claims description 45
- 238000000338 in vitro Methods 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 238000004519 manufacturing process Methods 0.000 claims description 34
- 230000035755 proliferation Effects 0.000 claims description 34
- 239000003112 inhibitor Substances 0.000 claims description 33
- 230000035558 fertility Effects 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 31
- 230000001850 reproductive effect Effects 0.000 claims description 27
- 101150090523 DAZL gene Proteins 0.000 claims description 25
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 24
- 238000002512 chemotherapy Methods 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 24
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 23
- 241000862969 Stella Species 0.000 claims description 22
- 238000002054 transplantation Methods 0.000 claims description 20
- 238000001959 radiotherapy Methods 0.000 claims description 19
- -1 caspase inhibitor Substances 0.000 claims description 18
- 210000001550 testis Anatomy 0.000 claims description 18
- 101100460583 Mus musculus Nobox gene Proteins 0.000 claims description 17
- 230000030833 cell death Effects 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 17
- 230000004720 fertilization Effects 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 17
- 208000000509 infertility Diseases 0.000 claims description 17
- 230000036512 infertility Effects 0.000 claims description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 16
- 210000003809 male germ line stem cell Anatomy 0.000 claims description 16
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 16
- 231100000535 infertility Toxicity 0.000 claims description 15
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000021595 spermatogenesis Effects 0.000 claims description 14
- 102000051485 Bcl-2 family Human genes 0.000 claims description 13
- 108700038897 Bcl-2 family Proteins 0.000 claims description 13
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 12
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 12
- 102000055102 bcl-2-Associated X Human genes 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 102000013814 Wnt Human genes 0.000 claims description 11
- 108050003627 Wnt Proteins 0.000 claims description 11
- 239000005557 antagonist Substances 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 10
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 10
- 210000000988 bone and bone Anatomy 0.000 claims description 10
- 229960002092 busulfan Drugs 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 229960004397 cyclophosphamide Drugs 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 10
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 9
- 102000003964 Histone deacetylase Human genes 0.000 claims description 9
- 108090000353 Histone deacetylase Proteins 0.000 claims description 9
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims description 9
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 9
- 108700012411 TNFSF10 Proteins 0.000 claims description 9
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims description 9
- 229940106189 ceramide Drugs 0.000 claims description 9
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 9
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 9
- 102100020880 Kit ligand Human genes 0.000 claims description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 210000004291 uterus Anatomy 0.000 claims description 7
- 102100038353 Gremlin-2 Human genes 0.000 claims description 6
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 210000002798 bone marrow cell Anatomy 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 230000000921 morphogenic effect Effects 0.000 claims description 6
- 230000001686 pro-survival effect Effects 0.000 claims description 6
- 210000001741 seminiferous epithelium Anatomy 0.000 claims description 6
- 241000237858 Gastropoda Species 0.000 claims description 5
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 5
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 229940123169 Caspase inhibitor Drugs 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 4
- 102100038367 Gremlin-1 Human genes 0.000 claims description 4
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 4
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 230000004853 protein function Effects 0.000 claims description 4
- 229930002330 retinoic acid Natural products 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- 229960001727 tretinoin Drugs 0.000 claims description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 3
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 3
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 3
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 3
- 229940044683 chemotherapy drug Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 231100001143 noxa Toxicity 0.000 claims description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 101710169778 Gremlin-2 Proteins 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010036049 Polycystic ovaries Diseases 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 108700000711 bcl-X Proteins 0.000 claims description 2
- 102000055104 bcl-X Human genes 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 4
- 210000005260 human cell Anatomy 0.000 claims 3
- 102000001267 GSK3 Human genes 0.000 claims 2
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 2
- 210000002308 embryonic cell Anatomy 0.000 claims 2
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000002893 dermoid cyst of ovary Diseases 0.000 claims 1
- 208000004971 ovarian teratoma Diseases 0.000 claims 1
- 229940076372 protein antagonist Drugs 0.000 claims 1
- 238000002955 isolation Methods 0.000 abstract description 8
- 230000014509 gene expression Effects 0.000 description 68
- 241000699670 Mus sp. Species 0.000 description 52
- 230000004069 differentiation Effects 0.000 description 43
- 230000006870 function Effects 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 30
- 239000003102 growth factor Substances 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 101000830428 Mus musculus ATP-dependent RNA helicase DDX4 Proteins 0.000 description 25
- 230000018109 developmental process Effects 0.000 description 25
- 238000011161 development Methods 0.000 description 23
- 238000010322 bone marrow transplantation Methods 0.000 description 22
- 238000012546 transfer Methods 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 102100037127 Developmental pluripotency-associated protein 3 Human genes 0.000 description 20
- 101100263436 Drosophila melanogaster vas gene Proteins 0.000 description 20
- 101100049051 Penaeus vannamei vasa gene Proteins 0.000 description 20
- 229940088597 hormone Drugs 0.000 description 19
- 239000005556 hormone Substances 0.000 description 19
- 210000000056 organ Anatomy 0.000 description 19
- 101000881866 Homo sapiens Developmental pluripotency-associated protein 3 Proteins 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 230000000144 pharmacologic effect Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 102100035970 Growth/differentiation factor 9 Human genes 0.000 description 12
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 101710204277 Growth/differentiation factor 9 Proteins 0.000 description 11
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 11
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 11
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 10
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 10
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 10
- 229940112869 bone morphogenetic protein Drugs 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 9
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 9
- 102100036235 Synaptonemal complex protein 3 Human genes 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 101710156847 CTD small phosphatase-like protein Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 210000002149 gonad Anatomy 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108010039471 Fas Ligand Protein Proteins 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 210000001082 somatic cell Anatomy 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 210000004340 zona pellucida Anatomy 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 101000976442 Homo sapiens Zona pellucida sperm-binding protein 3 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100023634 Zona pellucida sperm-binding protein 3 Human genes 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000012173 estrus Effects 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 230000005644 metestrus Effects 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000000392 somatic effect Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 239000013614 RNA sample Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000001654 germ layer Anatomy 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000021121 meiosis Effects 0.000 description 5
- 230000034004 oogenesis Effects 0.000 description 5
- 210000003101 oviduct Anatomy 0.000 description 5
- 239000002831 pharmacologic agent Substances 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 4
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 4
- 101001032860 Mus musculus Gremlin-2 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000009096 combination chemotherapy Methods 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000008627 meiotic prophase Effects 0.000 description 4
- 230000027758 ovulation cycle Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 101150021185 FGF gene Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 108700005087 Homeobox Genes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 3
- 229940083963 Peptide antagonist Drugs 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 108020001027 Ribosomal DNA Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003124 biologic agent Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- 238000009583 bone marrow aspiration Methods 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000004246 corpus luteum Anatomy 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000018853 germ cell migration Effects 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 229940094892 gonadotropins Drugs 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000002394 ovarian follicle Anatomy 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000004217 synaptonemal complex Anatomy 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- LFQXEZVYNCBVDO-PBJLWWPKSA-N 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC=C21 LFQXEZVYNCBVDO-PBJLWWPKSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
- 101150065175 Atm gene Proteins 0.000 description 2
- 108091007065 BIRCs Proteins 0.000 description 2
- 101100010325 Bos taurus DPPA3 gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- 102100037008 Factor in the germline alpha Human genes 0.000 description 2
- 101710123263 Factor in the germline alpha Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 101000988651 Homo sapiens Humanin-like 1 Proteins 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 206010024870 Loss of libido Diseases 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033165 Ovarian failure Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010088535 Pep-1 peptide Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000011509 clonal analysis Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003145 cytotoxic factor Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 210000004420 female germ cell Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000031776 germ cell proliferation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000012470 leptotene Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000863 loss of memory Toxicity 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 201000004535 ovarian dysfunction Diseases 0.000 description 2
- 231100000539 ovarian failure Toxicity 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000000624 ovulatory effect Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000005132 reproductive cell Anatomy 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000717 sertoli cell Anatomy 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- JLTPSDHKZGWXTD-UHFFFAOYSA-N 2-[6-(dicyanomethylidene)naphthalen-2-ylidene]propanedinitrile Chemical compound N#CC(C#N)=C1C=CC2=CC(=C(C#N)C#N)C=CC2=C1 JLTPSDHKZGWXTD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- DPEUWKZJZIPZKE-OFANTOPUSA-N 330936-69-1 Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 DPEUWKZJZIPZKE-OFANTOPUSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 description 1
- 101710161969 Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 101100014810 Caenorhabditis elegans glh-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 241000548230 Crassostrea angulata Species 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 102100033672 Deleted in azoospermia-like Human genes 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010023925 Histone Deacetylase 6 Proteins 0.000 description 1
- 102100028140 Homeobox protein NOBOX Human genes 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 1
- 101000871280 Homo sapiens Deleted in azoospermia-like Proteins 0.000 description 1
- 101001075110 Homo sapiens Growth/differentiation factor 9 Proteins 0.000 description 1
- 101000632048 Homo sapiens Homeobox protein NOBOX Proteins 0.000 description 1
- 101001037191 Homo sapiens Hyaluronan synthase 1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 102100040203 Hyaluronan synthase 1 Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100448240 Mus musculus Gdf9 gene Proteins 0.000 description 1
- 101001065566 Mus musculus Lymphocyte antigen 6A-2/6E-1 Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 241000549556 Nanos Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241001387976 Pera Species 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 102000015097 RNA Splicing Factors Human genes 0.000 description 1
- 108010039259 RNA Splicing Factors Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038967 Retrograde ejaculation Diseases 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 241000168914 Strepsirrhini Species 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 241001661355 Synapsis Species 0.000 description 1
- 101710143175 Synaptonemal complex protein 3 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 238000007800 T cell depleted bone marrow transplantation Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 241001454293 Tetranychus urticae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- 229930189037 Trapoxin Natural products 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010074006 Zona Pellucida Glycoproteins Proteins 0.000 description 1
- 102000008937 Zona Pellucida Glycoproteins Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000023752 cell cycle switching, mitotic to meiotic cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002336 epiblast cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001158 estrous effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000006543 gametophyte development Effects 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000011854 humanin Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 210000003794 male germ cell Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001785 maturational effect Effects 0.000 description 1
- 230000032969 meiotic prophase I Effects 0.000 description 1
- 210000003866 melanoblast Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000013152 negative regulation of cell migration Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003339 pole cell Anatomy 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000636 poly(norbornene) polymer Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000012781 shape memory material Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 231100000469 sperm hypomotility Toxicity 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 101150089602 vasa gene Proteins 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
- A61B17/43—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for artificial insemination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Definitions
- bone marrow derived germline stem cells can repopulate the germline of reproductive organs, and thus restore gonadal function.
- Methods of the invention relate to the use of bone marrow derived germline stem cells and their progenitors to, among other things, replenish or expand germ cell reserves of the testes and ovary, to enhance or restore fertility, and in females, to ameliorate symptoms and consequences of menopause.
- the present invention provides compositions comprising bone marrow derived female germline stem cells.
- the present invention provides compositions comprising bone marrow derived female germline stem cells, wherein the cells are mitotically competent and express Oct 4, Vasa, Dazl, Stella, Fragilis, and optionally Nobox, c-Kit and Sca-1. Consistent with their mitotically competent phenotype, bone marrow derived female germline stem cells of the invention do not express growth/differentiation factor-9 (“GDF-9”), zona pellucida proteins (e.g., zona pellucida protein-3, “ZP3”), histone deacetylase-6 (“HDAC6”) and synaptonemal complex protein-3 (“SCP3”).
- GDF-9 growth/differentiation factor-9
- ZP3 zona pellucida proteins
- HDAC6 histone deacetylase-6
- SCP3 synaptonemal complex protein-3
- bone marrow derived female germline stem cells of the invention can produce oocytes after a duration of at least 1 week, more preferably 1 to about 2 weeks, about 2 to about 3 weeks, about 3 to about 4 weeks or more than about 5 weeks post transplantation.
- the present invention provides compositions comprising progenitor cells derived from bone marrow derived female germline stem cells.
- the present invention provides compositions comprising bone marrow derived female germline stem cell progenitors, wherein the cells express Oct 4, Vasa, Dazl, Stella, Fragilis, and optionally Nobox, c-Kit and Sca-1 and wherein the cells do not express GDF-9, zona pellucida proteins, HDAC6 and SCP3.
- bone marrow derived female germline stem cell progenitors of the invention can produce oocytes after a duration of less than 1 week, preferably about 24 to about 48 hours post transplantation.
- the present invention provides an isolated bone marrow cell, wherein the cell is mitotically competent and expresses Oct 4, Vasa, Dazl, Stella, Fragilis, and optionally Nobox, c-Kit and Sca-1.
- the cell is a bone marrow derived female germline stem cell, or its progenitor cell, having an XX karyotype.
- the bone marow derived female germline stem cells, or their progenitor cells are non-embryonic, mammalian, and even more preferably, human.
- the present invention provides purified populations of bone marrow derived female germline stem cells and/or their progenitor cells.
- the purified population of cells is about 50 to about 55%, about 55 to about 60%, about 65 to about 70%, about 70 to about 75%, about 75 to about 80%, about 80 to about 85%, about 85 to about 90%, about 90 to about 95% or about 95 to about 100% of the cells in the composition.
- the present invention provides pharmaceutical compositions comprising bone marrow derived female germline stem cells, and/or their progenitor cells, and a pharmaceutically acceptable carrier.
- the pharmaceutical compositions can comprise purified populations of bone marrow derived female germline stem cells and/or their progenitor cells.
- Compositions comprising bone marrow derived female germline stem cells of the invention can be provided by direct administration to ovarian tissue, or indirect administration, for example, to the circulatory system of a subject (e.g., to the extra-ovarian circulation).
- the invention provides methods for manipulating bone marrow derived germline stem cells, or their progenitor cells, in vivo, ex vivo or in vitro as described herein below.
- the invention provides a method for expanding bone marrow derived female germline stem cells, or their progenitor cells, in vivo, ex vivo or in vitro, comprising contacting bone marrow derived female germline stem cells, or their progenitor cells, with an agent that increases the amount of bone marrow derived female germline stem cells, or their progenitor cells, by promoting proliferation or survival thereof, thereby expanding the bone marrow derived female germline stem cells, or their progenitor cells.
- the agent includes, but is not limited to, a hormone or growth factor (e.g., insulin-like growth factor (“IGF”), transforming growth factor (“TGF”), bone morphogenic protein (“BMP”), Wnt protein, or fibroblast growth factor (“FGF”)), a cell-signaling molecule (e.g., sphingosine-1-phosphate (“S1P”), or retinoic acid (“RA”)), or a pharmacological or pharmaceutical compound (e.g., an inhibitor of glycogen synthase kinase-3 (“GSK-3”), an inhibitor of apoptosis such as a Bax inhibitor or a caspase inhibitor, an inhibitor of nitric oxide production, or an inhibitor of HDAC activity).
- a hormone or growth factor e.g., insulin-like growth factor (“IGF”), transforming growth factor (“TGF”), bone morphogenic protein (“BMP”), Wnt protein, or fibroblast growth factor (“FGF”)
- the invention provides a method for identifying an agent that promotes proliferation or survival of a bone marrow derived female germline stem cell, or its progenitor cell, comprising contacting the bone marrow derived female germline stem cells, or their progenitor cells, with a test agent; and detecting an increase in the number of bone marrow derived female germline stem cells, or their progenitor cells, thereby identifying an agent that promotes proliferation or survival of a bone marrow derived female germline stem cell, or its progenitor cell.
- the invention provides a method for using the female germline stem cells, or their progenitor cells, to characterize pharmacogenetic cellular responses to biologic or pharmacologic agents, comprising isolating bone marrow derived female germline stem cells, or their progenitor cells, from a population of subjects, expanding said cells in culture to establish a plurality of cell cultures, optionally differentiating said cells into a desired lineage, contacting the cell cultures with one or more biologic or pharmacologic agents, identifying one or more cellular responses to the one or more biologic or pharmacologic agents, and comparing the cellular responses of the cell cultures from different subjects.
- the invention provides a method for oocyte production, comprising culturing a bone marrow derived female germline stem cell, or its progenitor cell, in the presence of an agent that differentiates a bone marrow derived female germline stem cell, or its progenitor cell, into an oocyte, thereby producing an oocyte.
- the agent includes, but is not limited to, a hormone or growth factor (e.g., a TGF, BMP or Wnt family protein, kit-ligand (“SCF”) or leukemia inhibitory factor (“LIF”)), a signaling molecule (e.g., meiosis-activating sterol, “FF-MAS”), or a pharmacologic or pharmaceutical agent (e.g., a modulator of Id protein function or Snail/Slug transcription factor function).
- a hormone or growth factor e.g., a TGF, BMP or Wnt family protein, kit-ligand (“SCF”) or leukemia inhibitory factor (“LIF”)
- SCF kit-ligand
- LIF leukemia inhibitory factor
- FF-MAS meiosis-activating sterol
- a pharmacologic or pharmaceutical agent e.g., a modulator of Id protein function or Snail/Slug transcription factor function
- the invention provides a method for in vitro fertilization of a female subject, said method comprising the steps of:
- the invention provides a method for in vitro fertilization of a female subject, said method comprising the steps of:
- the invention provides a method for identifying an agent that induces differentiation of a bone marrow derived female germline stem cell, or its progenitor cell, into an oocyte comprising contacting bone marrow derived female germline stem cells, or their progenitor cells, with a test agent; and detecting an increase in the number of oocytes, thereby identifying an agent that induces differentiation of a bone marrow derived female germline stem cell, or its progenitor.
- the present invention provides a method for oocyte production, comprising providing a bone marrow derived female germline stem cell, or its progenitor cell, to a tissue, preferably the ovary, wherein the cell engrafts into the tissue and differentiates into an oocyte, thereby producing an oocyte.
- the present invention provides a method for inducing folliculogenesis, comprising providing a bone marrow derived female germline stem cell, or its progenitor cell, to a tissue, preferably the ovary, wherein the cell engrafts into the tissue and differentiates into an oocyte within a follicle, thereby inducing folliculogenesis.
- the present invention provides a method for treating infertility in a female subject in need thereof comprising administering a therapeutically effective amount of a composition comprising bone marrow derived female germline stem cells, or their progenitor cells, to the subject, wherein the cells engraft into a tissue, preferably ovarian tissue, and differentiate into oocytes, thereby treating infertility.
- a composition comprising bone marrow derived female germline stem cells, or their progenitor cells, to the subject, wherein the cells engraft into a tissue, preferably ovarian tissue, and differentiate into oocytes, thereby treating infertility.
- the female subject in need of fertility treatment is not a subject who has undergone prior chemotherapy or radiotherapy.
- the present invention provides a method for restoring fertility to a female subject having undergone chemotherapy or radiotherapy (or both treatments) and who desires restored fertility, comprising administering a therapeutically effective amount of bone marrow derived female germline stem cells, or their progenitor cells, to the subject, wherein the cells engraft into a tissue, preferably ovarian tissue, and differentiate into oocytes, thereby restoring fertility in the subject.
- the bone marrow derived female germline stem cells comprise a purified sub-population of cells obtained from the bone marrow.
- Chemotherapeutic drugs include, but are not limited to, busulfan, cyclophosphamide, 5-FU, vinblastine, actinomycin D, etoposide, cisplatin, methotrexate, doxorubicin, among others.
- Radiotherapy includes, but is not limited to, ionizing radiation, ultraviolet radiation, X-rays, and the like.
- the present invention provides a method for protecting fertility in a female subject undergoing or expected to undergo chemotherapy or radiotherapy (or both treatments), comprising providing an agent that protects against reproductive injury prior to or concurrently with chemotherapy or radiotherapy (or both treatments) and providing a bone marrow derived female germline stem cell, or its progenitor cell, to the subject, wherein the cell engrafts into a tissue, preferably ovarian tissue, and differentiates into an oocyte, thereby protecting fertility in the subject.
- the protective agent can be S1P, a Bax antagonist, or any agent that increases SDF-1 activity.
- the present invention provides a method for repairing damaged ovarian tissue, comprising providing a therapeutically effective amount of a composition comprising bone marrow derived female germline stem cells, or their progenitor cells, to the tissue, wherein the cells engraft into the tissue and differentiate into oocytes, thereby repairing the damaged tissue.
- Damage can be caused, for example, by exposure to cytotoxic factors, hormone deprivation, growth factor deprivation, cytokine deprivation, cell receptor antibodies, and the like. Except where expressly stated herein, the damage is not caused by prior chemotherapy or radiotherapy. Damage can also be caused be diseases that affect ovarian function, including, but not limited to cancer, polycystic ovary disease, genetic disorders, immune disorders, metabolic disorders, and the like.
- the present invention provides a method for restoring ovarian function in a female subject having undergone chemotherapy or radiotherapy (or both treatments) and who desires restored ovarian function, comprising administering a therapeutically effective amount of bone marrow derived female germline stem cells, or their progenitor cells, to an ovary of the subject, wherein the cells engraft into the ovary and differentiate into oocytes within the ovary, thereby restoring ovarian function in the subject.
- the present invention provides a method for restoring ovarian function in a menopausal female subject, comprising administering a therapeutically effective amount of a composition comprising bone marrow derived female germline stem cells, or their progenitor cells, to the subject, wherein the cells engraft into the ovary and differentiate into oocytes, thereby restoring ovarian function.
- the menopausal female subject can be in a stage of either peri- or post-menopause, with said menopause caused by either normal (e.g., aging) or pathological (e.g., surgery, disease, ovarian damage) processes.
- Restoration of ovarian function can relieve adverse symptoms and complications associated with menopausal disorders, including, but not limited to, somatic disorders such as osteoporosis, cardiovascular disease, somatic sexual dysfunction, hot flashes, vaginal drying, sleep disorders, depression, irritability, loss of libido, hormone imbalances, and the like, as well as cognitive disorders, such as loss of memory; emotional disorders, depression, and the like.
- somatic disorders such as osteoporosis, cardiovascular disease, somatic sexual dysfunction, hot flashes, vaginal drying, sleep disorders, depression, irritability, loss of libido, hormone imbalances, and the like
- cognitive disorders such as loss of memory; emotional disorders, depression, and the like.
- the present invention provides compositions comprising bone marrow derived male germline stem cells, wherein the bone marrow derived male germline stem cells are mitotically competent and express Vasa and Dazl.
- Bone marrow derived male germline stem cells of the invention carry an XY karyotype
- bone marrow derived female germline stem cells of the invention carry an XX karyotype.
- the bone marrow derived male germline stem cells are non-embryonic, mammalian, and even more preferably, human.
- the invention provides an isolated bone marrow cell that is mitotically competent, has an XY kayrotype and expresses Vasa and Dazl.
- the present invention provides a method for restoring or enhancing spermatogenesis, comprising providing a bone marrow derived male germline stem cell, or its progenitor cell, to the testes of a male subject, wherein the cell engrafts into the seminiferous epithelium and differentiates into a sperm cell, thereby restoring or enhancing spermatogenesis.
- the present invention provides a method for restoring fertility to a male subject having undergone chemotherapy or radiotherapy (or both) and who desires restored fertility, comprising administering a therapeutically effective amount of bone marrow derived male germline stem cells, or their progenitor cells, to the subject, wherein the cells engraft into the seminiferous epithelium and differentiate into sperm cells, thereby restoring fertility.
- the invention provides a method for reducing the amount of bone marrow derived germline stem cells, or their progenitor cells, in vivo, ex vivo or in vitro, comprising contacting bone marrow derived germline stem cells, or their progenitor cells, with an agent that reduces cell proliferation, thereby reducing the amount of bone marrow derived germline stem cells, or their progenitor cells.
- the agent includes, but is not limited to, a hormone or growth factor (e.g., TGF- ⁇ ), a peptide antagonist of mitogenic hormones or growth factors (e.g., the BMP antagonists, Protein Related to DAN and Cerberus (“PRDC”) and Gremlin), or a pharmacological or pharmaceutical compound (e.g., a cell cycle inhibitor or an inhibitor of growth factor signaling).
- a hormone or growth factor e.g., TGF- ⁇
- a peptide antagonist of mitogenic hormones or growth factors e.g., the BMP antagonists, Protein Related to DAN and Cerberus (“PRDC”) and Gremlin
- PRDC Protein Related to DAN and Cerberus
- Gremlin a pharmacological or pharmaceutical compound
- the invention provides a method for reducing the amount of bone marrow derived germline stem cells, or their progenitor cells, in vivo, ex vivo or in vitro, comprising contacting bone marrow derived germline stem cells, or their progenitor cells, with an agent that inhibits cell survival or promotes cell death, thereby reducing the amount of bone marrow derived germline stem cells, or their progenitor cells.
- the agent the that inhibits cell survival includes, but is not limited to, a hormone, growth factor or cytokine (e.g., a pro-apoptotic tumor necrosis factor (“TNF”) super family member such as TNF- ⁇ , Fas-ligand (“FasL”) and TRAIL), an antagonist of pro-survival Bcl-2 family member function, a signaling molecule (e.g., a ceramide), or a pharmacological or pharmaceutical compound (e.g., an inhibitor of growth factor signaling).
- a hormone, growth factor or cytokine e.g., a pro-apoptotic tumor necrosis factor (“TNF”) super family member such as TNF- ⁇ , Fas-ligand (“FasL”) and TRAIL
- TNF tumor necrosis factor
- Fas-ligand Fas-ligand
- TRAIL a pro-survival Bcl-2 family member
- a signaling molecule e.g., a ceramide
- the agent the that promotes cell death includes, but is not limited to, a pro-apoptotic tumor necrosis factor superfamily member (e.g., TNF- ⁇ , FasL and TRAIL), agonist of pro-apoptotic Bcl-2 family member function and ceramide.
- a pro-apoptotic tumor necrosis factor superfamily member e.g., TNF- ⁇ , FasL and TRAIL
- agonist of pro-apoptotic Bcl-2 family member function e.g., apoptotic Bcl-2 family member function
- ceramide e.g., a pro-apoptotic tumor necrosis factor superfamily member
- the invention provides a method for identifying an agent that reduces proliferation or survival, or promotes cell death, of a bone marrow derived germline stem cell, or its progenitor cell, comprising contacting bone marrow derived germline stem cells, or their progenitor cells, with a test agent; and detecting a decrease in the number of bone marrow derived germline stem cells, or their progenitor cells, thereby identifying an agent that reduces proliferation or survival, or promotes cell death, of a female germline stem cell, or its progenitor cell.
- the present invention provides a method for contraception in a male or female subject comprising contacting bone marrow derived germline stem cells, or their progenitor cells, of the subject with an agent that decreases the proliferation, function or survival of bone marrow derived germline stem cells, or their progenitor cells, or the ability of said cells to produce new oocytes or sperm cells or other somatic cell types required for fertility, thereby providing contraception to the subject.
- the present invention provides kits for use in employing various agents of the invention.
- the present invention provides a kit for expanding a bone marrow derived female germline stem cell, or its progenitor cell, in vivo, ex vivo or in vitro, comprising an agent that promotes cell proliferation or survival of the bone marrow derived female germline stem cell, or its progenitor cell, and instructions for using the agent to promote cell proliferation or survival of the bone marrow derived female germline stem cell, or its progenitor, thereby expanding a female germline stem cell, or its progenitor cell in accordance with the methods of the invention.
- the present invention provides a kit for oocyte production, comprising an agent that differentiates a bone marrow derived female germline stem cell, or its progenitor cell, into an oocyte and instructions for using the agent to differentiate a bone marrow derived female germline stem cell, or its progenitor cell, into an oocyte in accordance with the methods of the invention.
- the present invention provides a kit for oocyte production, comprising an agent that increases the amount of bone marrow derived female germline stem cells, or their progenitor cells, by promoting proliferation or survival thereof, and instructions for using the agent to increase the amount of bone marrow derived female germline stem cells or their progenitor cells, thereby producing oocytes in accordance with the methods of the invention.
- the present invention provides a kit for oocyte production comprising an agent that differentiates bone marrow derived female germline stem cells, or their progenitor cells, into oocytes and instructions for using the agent to differentiate the bone marrow derived female germline stem cells, or their progenitor cells, into oocytes, thereby producing oocytes in accordance with the methods of the invention.
- the present invention provides a kit for treating infertility in a female subject in need thereof comprising an agent that increases the amount of bone marrow derived female germline stem cells, or their progenitor cells, by promoting proliferation or survival thereof and instructions for using the agent to increase the amount of bone marrow derived female germline stem cells or their progenitor cells, thereby treating infertility in the subject in accordance with the methods of the invention.
- the present invention provides a kit for treating infertility in a female subject in need thereof comprising an agent that differentiates bone marrow derived female germline stem cells, or their progenitor cells, into oocytes, and instructions for using the agent to differentiate bone marrow derived female germline stem cells, or their progenitor cells, into oocytes, thereby treating infertility in the subject in accordance with the methods of the invention.
- the present invention provides a kit for protecting fertility in a female subject undergoing or expected to undergo chemotherapy or radiotherapy (or both treatments), comprising an agent that that protects bone marrow derived female germline stem cells, or their progenitor cells, against reproductive injury and instructions for using the agent to protect bone marrow derived female germline stem cells, or their progenitor cells, against reproductive injury thereby protecting fertility in the female subject in accordance with the methods of the invention.
- the present invention provides a kit for restoring ovarian function in a post-menopausal female subject comprising an agent that increases the amount of bone marrow derived female germline stem cells, or their progenitor cells, by promoting proliferation or survival thereof and instructions for using the agent to increase the amount of bone marrow derived female germline stem cells or their progenitor cells, thereby restoring ovarian function in the subject in accordance with the methods of the invention.
- the present invention provides a kit for restoring ovarian function in a post-menopausal female subject comprising an agent that differentiates bone marrow derived female germline stem cells, or their progenitor cells, into oocytes, and instructions for using the agent to differentiate bone marrow derived female germline stem cells, or their progenitor cells, into oocytes, thereby restoring ovarian function in the subject in accordance with the methods of the invention.
- the present invention provides a kit for reducing the amount of bone marrow derived germline stem cells, or their progenitor cells, in vivo, ex vivo or in vitro, comprising an agent that inhibits cell survival or promotes cell death and instructions for using the agent to inhibit cell survival or promote cell death of the bone marrow derived germline stem cells, or their progenitor cells, thereby the reducing the amount of bone marrow derived germline stem cells, or their progenitor cells, in accordance with the methods of the invention.
- the present invention provides a kit for contraception in a male or female subject comprising an agent that decreases the proliferation, function or survival of bone marrow derived germline stem cells, or their progenitor cells, or the ability of said cells to produce new oocytes or other somatic cell types required for fertility and instructions for using the agent to decrease the proliferation, function or survival of bone marrow derived germline stem cells, or their progenitor cells, or the ability of said cells to produce new oocytes or sperm cells or other somatic cell types required for fertility, thereby providing contraception to the subject in accordance with the methods of the invention.
- FIG. 1 depicts an analysis of germ cells/progenitors in adult ovaries. Immunohistochemical analysis of SSEA1 expression (red, with nuclei highlighted by propidium iodide in blue) in adult mouse ovaries (B, higher magnification of stage-specific embryonic antigen 1+ (SSEA1) cells shown in A; A and C, ovaries from different mice). Single SSEA1+ cell in an adult ovary, showing cell surface expression of the antigen (D). Gene expression profile of isolated and residual cell fractions prepared from adult mouse ovaries following SSEA1 antibody-based magnetic bead sorting (E). The ribosomal gene, L7, was amplified as an internal loading control. No product was observed in any mock reverse-transcribed (Mock) ovarian RNA samples.
- SSEA1 stage-specific embryonic antigen 1+
- FIG. 2 indicates that bone marrow contains germ cells.
- Germline marker expression in bone marrow (BM) of adult wild-type female mice A.
- As a positive control for expression of germline markers adult mouse ovary RNA was analyzed in parallel.
- L7 ‘house-keeping’ gene.
- Mock mock reverse-transcribed RNA samples (B-C).
- D Mouse ovary analyzed in parallel as a positive control for the immunostaining shown in B-C, demonstrating a restricted expression of MVH (red) to germ cells (oocytes).
- FIG. 3 depicts properties of bone marrow-derived germ cells. Quantitative analysis of Mvh levels in crude (Total) and lineage-depleted (lin ⁇ ) bone marrow samples without or with further fractionation by FACS based on cell-surface expression of Sca-1 or c-Kit (A). All remaining lin ⁇ cells not represented in the Sca-1 ⁇ /c-Kit+ cell fraction were pooled and analyzed together. The data shown represent the combined results from an analysis of 3 adult female mice, with mean Mvh levels in the crude bone marrow sample set as the reference point for comparisons following normalization against beta-actin for sample loading.
- BM freshly isolated bone marrow.
- beta-actin ‘house-keeping’ gene.
- Mock mock reverse-transcribed RNA samples (B).
- FIG. 4 presents results indicating that bone marrow transplantation (BMT) reverses chemotherapy-induced ovarian failure.
- BMT bone marrow transplantation
- FIG. 5 presents results indicating that BMT sustains both short and long-term oocyte production in adult wild-type female mice sterilized by chemotherapy.
- FIG. 6 depicts the histology of postpartum day 4 wild-type ( FIG. 6A , magnified in FIG. 6C ) and Atm-null ( FIG. 6B , magnified in FIG. 6D ) ovaries.
- Representative histology of adult wild-type ( FIG. 6E ) and Atm-null ( FIG. 6F ) ovaries from adult mice is also shown.
- FIG. 7 depicts expression of germline marker genes in Atm deficient mouse ovaries by RT-PCR analysis of Oct4, Mvh (Vasa), Dazl and Stella expression in ovaries of adult Atm-null ( ⁇ / ⁇ ) female mice.
- the ribosomal gene, L7 was amplified as an internal loading control; no product was observed in mock reverse-transcribed (Mock) ovarian RNA samples.
- FIG. 8 depicts ovaries in a chemotherapy conditioned (busulfan, cyclophosphamide) Atm-null mouse that received exogenous, wild-type bone marrow. Both the wild-type mouse and the Atm-null mouse that received exogenous, wild-type bone marrow after sterilizing doses of chemotherapy exhibited normal oocytes within normal appearing follicles.
- FIG. 9 depicts analysis of germline markers in bone marrow of humans. Expression of DAZL and STELLA in bone marrow collected from 4 human female donors between 24-36 years of age. As a negative control, germline markers were not detected in two different adult human uterine (Ut) endometrial samples analyzed in parallel. Glyceraldehyde 3 phosphate dehydrogenase (GAPDH), a house keeping gene, amplified as an internal loading control. Mock, mock reverse-transcribed RNA samples.
- Glyceraldehyde 3 phosphate dehydrogenase Glyceraldehyde 3 phosphate dehydrogenase
- Mock mock reverse-transcribed RNA samples.
- Bone marrow derived germline stem cells are any multipotent cells obtained from bone marrow that include a population of female or male germline stem cells.
- “Expansion” refers to the propagation of a cell or cells without terminal differentiation. “Isolation phenotype” refers to the structural and functional characteristics of the bone marrow derived germline stem cells upon isolation. “Expansion phenotype” refers to the structural and functional characteristics of the bone marrow derived germline stem cells during expansion. The expansion phenotype can be identical to the isolation phenotype, or alternatively, the expansion phenotype can be more differentiated than the isolation phenotype.
- “Differentiation” refers to the developmental process of lineage commitment.
- a “lineage” refers to a pathway of cellular development, in which precursor or “progenitor” cells undergo progressive physiological changes to become a specified cell type having a characteristic function (e.g., nerve cell, muscle cell or endothelial cell). Differentiation occurs in stages, whereby cells gradually become more specified until they reach full maturity, which is also referred to as “terminal differentiation.”
- a “terminally differentiated cell” is a cell that has committed to a specific lineage, and has reached the end stage of differentiation (i.e., a cell that has fully matured). Oocytes are an example of a terminally differentiated cell type.
- isolated refers to a bone marrow derived germline stem cell or its progenitor cell, in a non-naturally occurring state (e.g., isolated from the body or a biological sample, such as bone marrow, from the body).
- Progenitor cells as used herein are germ lineage cells that are 1) derived from germline stem cells of the invention as the progeny thereof which contain a set of common marker genes; 2) are in an early stage of differentiation; and 3) retain mitotic capacity.
- Progeny as used herein are all cells derived from bone marrow derived germline stem cells of the invention, including progenitor cells, differentiated cells, and terminally differentiated cells.
- “Derived from” as used herein refers to the process of obtaining a daughter cell.
- Endgraft refers to the process of cellular contact and incorporation into an existing tissue of interest (e.g., ovary) in vivo.
- Agents refer to cellular (e.g., biologic) and pharmaceutical factors, preferably growth factors, cytokines, hormones or small molecules, or to genetically-encoded products that modulate cell function (e.g., induce lineage commitment, increase expansion, inhibit or promote cell growth and survival).
- expansion agents are agents that increase proliferation and/or survival of bone marrow derived germline stem cells.
- “Differentiation agents” are agents that induce bone marrow derived germline stem cells to differentiate into committed cell lineages, such as oocytes and sperm cells.
- a “follicle” refers to an ovarian structure consisting of a single oocyte surrounded by somatic (granulosa without or with theca-interstitial) cells. Somatic cells of the gonad enclose individual oocytes to form follicles. Each fully formed follicle is enveloped in a complete basement membrane. Although some of these newly formed follicles start to grow almost immediately, most of them remain in the resting stage until they either degenerate or some signal(s) activate(s) them to enter the growth phase.
- ovarian structure, function and physiology see Gougeon, A., (1996) Endocr Rev. 17:121-55; Anderson, L. D., and Hirshfield, A. N. (1992) Md Med J. 41: 614-20; and Hirshfield, A. N. (1991) Int Rev Cytol. 124: 43-101.
- a “sperm cell” refers to a male germ cell, in either a pre-meiotic (i.e., mitotically competent) or post-meiotic state of development, including a fully mature spermatozoan. “Spermatogenesis” is the developmental process by which a sperm cell is formed.
- Mitotically competent refers to a cell that is capable of mitosis, the process by which a cell divides and produces two daughter cells from a single parent cell.
- non-embryonic cell refers to a cell that is obtained from a post-natal source (e.g., infant, child or adult tissue).
- a “subject” is a vertebrate, preferably a mammal, more preferably a primate and still more preferably a human. Mammals include, but are not limited to, primates, humans, farm animals, sport animals, and pets.
- obtaining as in “obtaining the agent” is intended to include purchasing, synthesizing or otherwise acquiring the agent (or indicated substance or material).
- one or more mechanisms can be involved with the ability of bone marrow derived germline stem cells to repopulate reproductive organs.
- Female germline stem cells have been detected in the bone marrow, which may therefore serve as a reservoir for stem cells having the capacity to repopulate and/or expand the germ cell supply of reproductive organs.
- Male germline stem cells also exist in the bone marrow of male subjects.
- Other sub-populations of cells in the bone marrow, such as hematopoietic stem cells may likewise have the ability to repopulate and/or expand the germ cell supply of reproductive organs (Herzog, E.
- Bone marrow derived female germline stem cells express markers including Oct 4, Vasa, Dazl, Stella, Fragilis, and optionally Nobox, c-Kit and Sca-1. Bone marrow derived female germline stem cells are mitotically competent (i.e., capable of mitosis) and accordingly, do not express GDF-9, zona pellucida proteins (e.g., ZP3), HDAC6 or SCP3.
- the present invention also provides bone marrow derived female germline stem cell progenitors.
- Bone marrow derived female germline stem cell progenitors of the invention can circulate throughout the body and most preferably can be localized in bone marrow, peripheral blood and ovary.
- Progenitor cells of the invention express Oct 4, Vasa, Dazl, Stella, Fragilis, and optionally Nobox, c-Kit and Sca-1 but do not express GDF-9, zona pellucida proteins (e.g., ZP3), HDAC6 or SCP3.
- Bone marrow derived female germline stem cells and their progenitor cells have functional distinctions.
- bone marrow derived female germline stem cells of the invention can produce oocytes after a duration of at least 1 week, more preferably 1 to about 2 weeks, about 2 to about 3 weeks, about 3 to about 4 weeks or more than about 5 weeks post transplantation.
- Bone marrow derived female germline stem cell progenitors have the capacity to generate oocytes more rapidly than bone marrow derived female germline stem cells.
- bone marrow derived female germline stem cell progenitors of the invention can produce oocytes after a duration of less than 1 week, preferably about 24 to about 48 hours post transplantation.
- Oct-4 is a gene expressed in bone marrow derived female germline stem cells and their progenitor cells.
- the Oct-4 gene encodes a transcription factor that is involved in the establishment of the mammalian germline and plays a significant role in early germ cell specification (reviewed in Scholer (1991), Trends Genet. 7(10): 323-329).
- Oct-4 is downregulated during the differentiation of the epiblast, eventually becoming confined to the germ cell lineage.
- Oct-4 expression is regulated separately from epiblast expression.
- Expression of Oct-4 is a phenotypic marker of totipotency (Yeom et al. (1996), Development 122: 881-888).
- Stella is a gene expressed in bone marrow derived female germline stem cells and their progenitor cells. Stella is a novel gene specifically expressed in primordial germ cells and their descendants, including oocytes (Bortvin et al. (2004) BMC Developmental Biology 4(2):1-5). Stella encodes a protein with a SAP-like domain and a splicing factor motif-like structure. Embryos deficient in Stella expression are compromised in preimplantation development and rarely reach the blastocyst stage. Thus, Stella is a maternal factor implicated in early embryogenesis.
- Dazl is a gene expressed in bone marrow derived female germline stem cells and their progenitor cells.
- the autosomal gene Dazl is a member of a family of genes that contain a consensus RNA binding domain and are expressed in germ cells. Loss of expression of an intact Dazl protein in mice is associated with failure of germ cells to complete meiotic prophase. Specifically, in female mice null for Dazl, loss of germ cells occurs during fetal life at a time coincident with progression of germ cells through meiotic prophase. In male mice null for Dazl, germ cells were unable to progress beyond the leptotene stage of meiotic prophase I. Thus, in the absence of Dazl, progression through meiotic prophase is interrupted (Saunders et al. (2003), Reproduction, 126:589-597).
- Vasa is a gene expressed in bone marrow derived female germline stem cells and their progenitor cells.
- Vasa is a component of the germplasm that encodes a DEAD-family ATP-dependent RNA helicase (Liang et al. (1994) Development, 120:1201-1211; Lasko et al. (1988) Nature, 335:611-167).
- the molecular function of Vasa is directed to binding target mRNAs involved in germ cell establishment (e.g., Oskar and Nanos), oogenesis, (e.g., Gruken), and translation onset (Gavis et al. (1996) Development, 110: 521-528).
- Vasa is required for pole cell formation and is exclusively restricted to the germ cell lineage throughout the development.
- Vasa is a molecular marker for the germ cell lineage in most animal species (Toshiaki et al. (2001) Cell Structure and Function 26:131-136). Because Vasa has been associated with inhibition of cell migration, expression of Vasa in progenitor cells of the invention may be differentially regulated, depending on the migratory state of the progenitor. For example, while in the bone marrow, the progenitor may express Vasa, and while migrating to the reproductive tract, the progenitor may down regulate expression.
- Fragilis is a gene expressed in bone marrow derived female germline stem cells and their progenitor cells. Fragilis is a putative interferon-inducible gene that codes for a transmembrane protein associated with the acquisition of germ cell competence by epiblast cells (Saitou, M. et al. (2002) Nature 418:293-300). Extraembryonic ectoderm is able to induce fragilis expression in epiblast tissue. Fragilis is expressed in proximal epiblast at a region in which primordial germ cell (PGC)-competent cells reside according to clonal analysis (Lawson, K A et al. (1994) In Wiley, Chichester (Ciba Foundation Symposium 182): 68-91).
- PPC primordial germ cell
- fragilis expression increases within a community of cells at the base of the incipient allantoic bud.
- Cells with the highest expression of fragilis initiate the germ cell-characteristic expression of TNAP and stella/PGC-7 (Ginsburg, M. et al. (1990) Development 110:521-528; Sato, M. et al. (2002) Mech Dev 113:91-94) and show repression of Hox genes.
- Nobox is a gene that is optionally expressed in bone marrow derived female germline stem cells and their progenitor cells.
- Nobox (Newborn Ovary Homeobox) is a gene active in ovaries and testes that regulates the transition of a primordial germ cell into a primary follicle.
- Female mice lacking the Nobox gene lose all of their follicles by 6 weeks of life and are essentially menopausal by that time; males have normal testes but are 30% less fertile (Rajkovic, A. et al. (2004) Science 305 (5687): 1157-1159).
- Nobox appears to govern the activity of genes crucial to the development of follicles, which hold the immature eggs cells or oocytes. These follicles are supposed to thicken as the mouse develops; without Nobox, the follicles do not develop, and the oocytes deteriorate.
- c-kit mRNA and protein are germ cell specific in human fetal gonads and are consistent with an important role for the c-kit/kit ligand signalling system in germ cell proliferation and survival in the developing human gonad (Robinson, L. L., et al. (2001) Mol Hum Reprod 7(9):845-52).
- Sca-1 is a gene that is optionally expressed in bone marrow derived female germline stem cells and their progenitor cells.
- Sca-1 stem cell antigen 1, Ly-6A/E
- Sca-1 stem cell antigen 1, Ly-6A/E
- Sca-1 has been used in the isolation of hematopoietic stem cells (purification to homogeneity) from mouse bone marrow (Van de Rijn, M. et al. (1989) Proc. Natl. Acad. Sci. USA 86:4634; Spangrude, G. I. et al. (1988) Science 241:58).
- Sca-1 + HSCs can be found in the adult bone marrow, fetal liver and mobilized peripheral blood and spleen within the adult animal (Morrison, S. J. et al. (1997) Proc. Natl. Acad. Sci. USA 94:1908). Additionally, Sca-1 may be involved in regulating both B and T cell activation (Codias, E. K. et al. (1990) J. Immunol. 145:1407).
- GDF-9 a gene expressed in cells that have already started to differentiate into oocytes.
- Growth/differentiation factor-9 (GDF-9) is a member of the transforming growth factor- ⁇ superfamily, expressed specifically in ovaries. GDF-9 mRNA can be found in neonatal and adult oocytes from the primary one-layer follicle stage until after ovulation (Dong, J. et al (1996) Nature 383: 531-5). Analysis of GDF-9 deficient mice reveals that only primordial and primary one-layer follicles can be formed, but a block beyond the primary one-layer follicle stage in follicular development occurs, resulting in complete infertility.
- Bone marrow derived female germline stem cells and their progenitor cells do not express ZP1, ZP2, and ZP3, which are gene products that comprise the zona pellucida of the oocyte. Their expression is regulated by a basic helix-loop-helix (bHLH) transcription factor, FIG ⁇ . Mice null in FIG ⁇ do not express the Zp genes and do not form primordial follicles (Soyal, S. M., et al (2000) Development 127: 4645-4654). Individual knockouts of the ZP genes result in abnormal or absent zonae pellucidae and decreased fertility (Zp 1; Rankin T, et al (1999) Development.
- Zp 1 Rankin T, et al (1999) Development.
- ZP protein products are glycosylated, and subsequently secreted to form an extracellular matrix, which is important for in vivo fertilization and pre-implantation development. Expression of the ZP proteins is precisely regulated and restricted to a two-week growth phase of oogenesis. Zp mRNA transcripts are not expressed in resting oocytes, however once the oocytes begin to grow, all three Zp transcripts begin to accumulate.
- HDAC6 Bone marrow derived female germline stem cells and their progenitor cells do not express HDAC6.
- HDACs, or histone deacetylases are involved in ovarian follicle development. HDAC6 in particular can be detected in resting germinal vesicle-stage (primordial) oocytes (Verdel, A., et al. (2003) Zygote 11: 323-8; FIG. 16 ). HDAC6 is a class II histone deacetylase and has been implicated as a microtubule-associated deactylase (Hubbert, C. et al, (2002) Nature 417: 455-8). HDACs are the target of inhibitors including, but not limited to, trichostatin A and trapoxin, both of which are microbial metabolites that induce cell differentiation, cell cycle arrest, and reversal of the transformed cell morphology.
- Bone marrow derived female germline stem cells and their progenitor cells can be isolated by standard means known in the art for the separation of stem cells from the marrow (e.g., cell sorting).
- the isolation protocol includes generation of a kit + /lin ⁇ fraction that is depleted of hematopoietic cells. Additional selection means based on the unique profile of gene expression (e.g., Vasa, Oct-4, Dazl, Stella, Fragilis) can be employed to further purify populations of cells comprising bone marrow derived female germline stem cells and their progenitor cells.
- Compositions comprising bone marrow derived female germline stem cells and their progenitor cells can be isolated and subsequently purified to an extent where they become substantially free of the biological sample from which they were obtained (e.g. bone marrow).
- Bone marrow derived female germline stem cell progenitors can be obtained from female germline stem cells by, for example, expansion in culture.
- the progenitor cells can be cells having an “expansion phenotype.”
- compositions comprising bone marrow derived germline stem cells or their progenitor cells can be provided directly to the reproductive organ of interest (e.g., ovary or testes).
- compositions comprising bone marrow derived germline stem cells or their progenitors can be provided indirectly to the reproductive organ of interest, for example, by administration into the circulatory system (e.g., to the extra-ovarian circulation).
- the cells can engraft and differentiate into germ cells (e.g., oocytes or sperm cells).
- Engraft refers to the process of cellular contact and incorporation into an existing tissue of interest (e.g., ovary) in vivo. Expansion and differentiation agents can be provided prior to, during or after administration to increase production of germ cells in vivo.
- compositions of the invention include pharmaceutical compositions comprising bone marrow derived germline stem cells or their progenitor cells and a pharmaceutically acceptable carrier.
- Administration can be autologous or heterologous.
- bone marrow derived germline stem cells, or their progenitor cells can be obtained from one subject, and administered to the same subject or a different, compatible subject.
- Bone marrow derived germline stem cells of the invention or their progeny can be administered via localized injection, including catheter administration, systemic injection, localized injection, intravenous injection, intrauterine injection or parenteral administration.
- a therapeutic composition of the present invention e.g., a pharmaceutical composition
- it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion).
- compositions of the invention can be conveniently provided as sterile liquid preparations, e.g., isotonic aqueous solutions, suspensions, emulsions, dispersions, or viscous compositions, which may be buffered to a selected pH.
- Liquid preparations are normally easier to prepare than gels, other viscous compositions, and solid compositions. Additionally, liquid compositions are somewhat more convenient to administer, especially by injection. Viscous compositions, on the other hand, can be formulated within the appropriate viscosity range to provide longer contact periods with specific tissues.
- Liquid or viscous compositions can comprise carriers, which can be a solvent or dispersing medium containing, for example, water, saline, phosphate buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like) and suitable mixtures thereof.
- carriers can be a solvent or dispersing medium containing, for example, water, saline, phosphate buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like) and suitable mixtures thereof.
- compositions can be isotonic, i.e., they can have the same osmotic pressure as blood and lacrimal fluid.
- the desired isotonicity of the compositions of this invention may be accomplished using sodium chloride, or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol or other inorganic or organic solutes.
- Sodium chloride is preferred particularly for buffers containing sodium ions.
- liquid dosage form e.g., whether the composition is to be formulated into a solution, a suspension, gel or another liquid form, such as a time release form or liquid-filled form.
- a method to potentially increase cell survival when introducing the cells into a subject in need thereof is to incorporate bone marrow derived germline stem cells or their progeny (e.g., in vivo, ex vivo or in vitro derived) of interest into a biopolymer or synthetic polymer.
- the site of injection might prove inhospitable for cell seeding and growth because of scarring or other impediments.
- biopolymer include, but are not limited to, cells mixed with fibronectin, fibrin, fibrinogen, thrombin, collagen, and proteoglycans. This could be constructed with or without included expansion or differentiation factors. Additionally, these could be in suspension, but residence time at sites subjected to flow would be nominal.
- Another alternative is a three-dimensional gel with cells entrapped within the interstices of the cell biopolymer admixture. Again, expansion or differentiation factors could be included with the cells. These could be deployed by injection via various routes described herein.
- bone marrow derived germline stem cells are the quantities of cells necessary to achieve an optimal effect.
- empirical doses ranging from 1 to 4 ⁇ 10 7 cells have been used with encouraging results.
- different scenarios may require optimization of the amount of cells injected into a tissue of interest.
- the quantity of cells to be administered will vary for the subject being treated. In a preferred embodiment, between 10 4 to 10 8 , more preferably 10 5 to 10 7 , and still more preferably, 3 ⁇ 10 7 stem cells of the invention can be administered to a human subject.
- Less cells can be administered directly to the ovary or testes.
- 10 2 to 10 6 Preferably, between 10 2 to 10 6 , more preferably 10 3 to 10 5 , and still more preferably, 10 4 bone marrow derived germline stem cells can be administered to a human subject.
- the precise determination of what would be considered an effective dose may be based on factors individual to each patient, including their size, age, sex, weight, and condition of the particular patient. As few as 100-1000 cells can be administered for certain desired applications among selected patients. Therefore, dosages can be readily ascertained by those skilled in the art from this disclosure and the knowledge in the art.
- Bone marrow derived germline stem cells of the invention can comprise a purified population of germline stem cells or their progenitors. Those skilled in the art can readily determine the percentage of cells in a population using various well-known methods, such as fluorescence activated cell sorting (FACS). Preferable ranges of purity in populations comprising female germline stem cells or their progenitors are about 50 to about 55%, about 55 to about 60%, and about 65 to about 70%. More preferably the purity is about 70 to about 75%, about 75 to about 80%, about 80 to about 85%; and still more preferably the purity is about 85 to about 90%, about 90 to about 95%, and about 95 to about 100%. Purity of female germline stem cells or their progenitors can be determined according to the cell surface marker profile within a population. Dosages can be readily adjusted by those skilled in the art (e.g., a decrease in purity may require an increase in dosage).
- FACS fluorescence activated cell sorting
- any additives in addition to the active stem cell(s) and/or agent(s) are present in an amount of 0.001 to 50% (weight) solution in phosphate buffered saline, and the active ingredient is present in the order of micrograms to milligrams, such as about 0.0001 to about 5 wt %, preferably about 0.0001 to about 1 wt %, still more preferably about 0.0001 to about 0.05 wt % or about 0.001 to about 20 wt %, preferably about 0.01 to about 10 wt %, and still more preferably about 0.05 to about 5 wt %.
- any composition to be administered to an animal or human it is preferred to determine therefore: toxicity, such as by determining the lethal dose (LD) and LD 50 in a suitable animal model e.g., rodent such as mouse; and, the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit a suitable response.
- toxicity such as by determining the lethal dose (LD) and LD 50 in a suitable animal model e.g., rodent such as mouse
- LD 50 lethal dose
- LD 50 low-d dose
- suitable animal model e.g., rodent such as mouse
- the dosage of the composition(s), concentration of components therein and timing of administering the composition(s) which elicit a suitable response.
- the engrafted cells undergo folliculogenesis, wherein the cells differentiate into an oocyte and become enclosed within a follicle.
- the engrafted cells differentiate into an oocyte within a follicle of the ovary.
- Folliculogenesis is a process in which an ovarian structure consisting of a single oocyte is surrounded by somatic (granulosa without or with theca-interstitial) cells. Somatic cells of the gonad enclose individual oocytes to form follicles. Each fully formed follicle is enveloped in a complete basement membrane.
- a method of the invention can induce folliculogenesis by providing a bone marrow derived female germline stem cell, or its progenitor, to a tissue (e.g., ovarian tissue) by any one of several routes of administration.
- the bone marrow derived female germline stem cell, or its progenitor can engraft into the tissue and differentiate into an oocyte within a follicle.
- the number of bone marrow derived female germline stem cells, or their progenitor cells can be increased by increasing the survival or proliferation of existing bone marrow derived female germline stem cells, or their progenitor cells.
- the peptide humanin is an inhibitor of Bax function that suppresses apoptosis (Guo, B. et al, (2003) Nature 423: 456-461).
- the contents of each of these references are specifically incorporated herein by reference for their description of expansion agents known in the art.
- Oocyte production can be further increased by contacting bone marrow derived female germline stem cells, or their progenitor cells, with an agent that differentiates bone marrow derived female germline stem cells or their progenitor cells into oocytes (e.g., differentiation agents).
- differentiation agents include, but are not limited to, a hormone or growth factor (e.g., TGF, BMP, Wnt protein, SCF or LIF), a signaling molecule (e.g., meiosis-activating sterol, “FF-MAS”), or a pharmacologic or pharmaceutical agent (e.g., a modulator of Id protein function or Snail/Slug transcription factor function).
- TGF- ⁇ can induce differentiation of hematopoietic stem cells
- TGF- ⁇ can induce differentiation of hematopoietic stem cells
- U.S. Patent Application No. 2002142457 describes methods for differentiation of cardiomyocytes using BMPs. Pera et al describe human embryonic stem cell differentiation using BMP-2 (Pera, M. F. et al, (2004) J. Cell Sci. 117: 1269).
- U.S. Patent Application No. 20040014210 and U.S. Pat. No. 6,485,972 describe methods of using Wnt proteins to induce differentiation.
- Agents comprising signaling molecules are also known to induce differentiation of oocytes.
- FF-Mas is known to promote oocyte maturation (Marin Bivens, C. L. et al, (2004) BOR papers in press). The contents of each of these references are specifically incorporated herein by reference for their description of differentiation agents known in the art.
- Agents comprising pharmacological or pharmaceutical compounds are also known in the art to induce differentiation of stem cells.
- modulators of Id are involved in hematopoietic differentiation (Nogueria, M. M. et al, (2000) 276: 803) and Modulators of Snail/Slug are known to induce stem cell differentiation (Le Douarin, N. M. et al, (1994) Curr. Opin. Genet. Dev. 4: 685-695; Plescia, C. et al, (2001) Differentiation 68: 254).
- the contents of each of these references are specifically incorporated herein by reference for their description of differentiation agents known in the art.
- the present invention also provides methods for reducing bone marrow derived female germline stem cells, or their progenitor cells, in vivo, ex vivo or in vitro, comprising contacting bone marrow derived female germline stem cells or their progenitor cells with an agent that reduces cell proliferation, inhibits cell survival or promotes cell death.
- Unwanted proliferation of the cells of the invention can give rise to cancerous and pre-cancerous phenotypes (e.g., germ cell tumors, ovarian cancer).
- Such methods can be used to control unwanted proliferation (e.g., cancer) or for contraceptive measures by reducing the numbers of germline stem cells, and optionally their progenitors or oocytes.
- Agents that reduce cell proliferation include, but are not limited to, a hormone or growth factor (e.g., TGF- ⁇ ), a peptide antagonist of mitogenic hormones or growth factors (e.g., the BMP antagonists, PRDC and Gremlin), or a pharmacological or pharmaceutical compound (e.g., a cell cycle inhibitor, or an inhibitor of growth factor signaling).
- a hormone or growth factor e.g., TGF- ⁇
- a peptide antagonist of mitogenic hormones or growth factors e.g., the BMP antagonists, PRDC and Gremlin
- a pharmacological or pharmaceutical compound e.g., a cell cycle inhibitor, or an inhibitor of growth factor signaling.
- Agents that inhibit cell survival include, but are not limited to, a hormone, growth factor or cytokine (e.g., a pro-apoptotic TNF super family member such as TNF- ⁇ , FasL and TRAIL), an antagonist of pro-survival Bcl-2 family member function, a signaling molecule (e.g., a ceramide), or a pharmacological or pharmaceutical compound (e.g., an inhibitor of growth factor signaling).
- a hormone, growth factor or cytokine e.g., a pro-apoptotic TNF super family member such as TNF- ⁇ , FasL and TRAIL
- an antagonist of pro-survival Bcl-2 family member function e.g., a signaling molecule (e.g., a ceramide), or a pharmacological or pharmaceutical compound (e.g., an inhibitor of growth factor signaling).
- Pro-survival Bcl-2 family members include Bcl-2, Bcl-xl (
- Agents that promote cell death include, but are not limited to, a pro-apoptotic tumor necrosis factor superfamily member (e.g., TNF- ⁇ , FasL and TRAIL), agonist of pro-apoptotic Bcl-2 family member function and ceramide.
- Pro-apoptotic Bcl-2 family members include Bax (Oltvai, Z N, et al. (1993): Cell 74: 609-619), Bak (Chittenden, T, et al. (1995) Nature 374:733-736), Bid (Luo, X., et al. (1998) Cell 94:481-490), Hrk (Inohara, N. et al. (1997) EMBO J.
- Bod Hsu, et al. (1998) Mol Endocrinol. 12(9):1432-1440), Bim (O'Connor, L., et al. (1998) EMBO J. 17(2):385-395), Noxa (Oda, E., et al. (2000) Science 288, 1053-1058; Yakovlev, A. G., et al. (2004) J Biol Chem 279(27):28367-28374), puma (Nakano, K. and Vousden, K. H. (2001) Mol Cell 7(3):683-694), Bok (Yakovlev, A. G., et al.
- Bcl-2 family members such as Bcl-2, Bcl-XL, Bcl-W, Mcl-1, A1, Bax, Bak, Bid, Hrk, Bod, Bim, Noxa, Puma, Bok and Bcl-xs, are known to inhibit stem cell survival (Lindsten, T. et al, (2003) J. Neurosci. 23: 11112-9).
- Agents comprising pharmacological or pharmaceutical compounds are also known in the art to inhibit cell survival.
- inhibitors of growth factor signaling such as QSulfl, a heparan sulfate 6-O-endosulfatase that inhibits fibroblast growth factor signaling, can inhibit stem cell survival (Wang, S. et al, (2004) Proc. Natl. Acad. Sci. USA 101: 4833).
- stem cell survival Wang, S. et al, (2004) Proc. Natl. Acad. Sci. USA 101: 4833.
- the contents of each of these references are specifically incorporated herein by reference for their description of agents known in the art to inhibit cell survival.
- Agents can be provided directly to the reproductive organ of interest.
- agents can be provided indirectly to the reproductive organ of interest, for example, by administration into the circulatory system.
- Agents can be administered to subjects in need thereof by a variety of administration routes.
- Methods of administration may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects.
- modes of administration include oral, rectal, topical, intraocular, buccal, intravaginal, intracisternal, intracerebroventricular, intratracheal, nasal, transdermal, within/on implants, e.g., fibers such as collagen, osmotic pumps, or grafts comprising appropriately transformed cells, etc., or parenteral routes.
- parenteral includes subcutaneous, intravenous, intramuscular, intraperitoneal, intragonadal or infusion.
- Intravenous or intramuscular routes are not particularly suitable for long-term therapy and prophylaxis.
- a particular method of administration involves coating, embedding or derivatizing fibers, such as collagen fibers, protein polymers, etc. with therapeutic proteins.
- Other useful approaches are described in Otto, D. et al., J. Neurosci. Res. 22: 83 and in Otto, D. and Unsicker, K. J. Neurosci. 10: 1912.
- In vitro and ex vivo applications can involve culture of the bone marrow derived germline stem cells or their progenitors with the selected agent to achieve the desired result. Cultures of cells (from the same individual and from different individuals) can be treated with differentiation agents of interest to stimulate, for example, the production of oocytes or sperm cells, which can then be used for a variety of therapeutic applications (e.g., in vitro fertilization).
- Differentiated cells derived from cultures of the invention can be implanted into a host.
- the transplantation can be autologous, such that the donor of the stem cells from which organ or organ units are derived is the recipient of the engineered tissue.
- the transplantation can be heterologous, such that the donor of the stem cells from which organ or organ units are derived is not that of the recipient of the engineered-tissue.
- Bone marrow derived germline stem cells and the progeny thereof can be cultured, treated with agents and/or administered in the presence of polymer scaffolds.
- Polymer scaffolds are designed to optimize gas, nutrient, and waste exchange by diffusion.
- Polymer scaffolds can comprise, for example, a porous, non-woven array of fibers.
- the polymer scaffold can be shaped to maximize surface area, to allow adequate diffusion of nutrients and growth factors to the cells. Taking these parameters into consideration, one of skill in the art could configure a polymer scaffold having sufficient surface area for the cells to be nourished by diffusion until new blood vessels interdigitate the implanted engineered-tissue using methods known in the art.
- Polymer scaffolds can comprise a fibrillar structure.
- the fibers can be round, scalloped, flattened, star-shaped, solitary or entwined with other fibers. Branching fibers can be used, increasing surface area proportionately to volume.
- the term “polymer” includes polymers and monomers that can be polymerized or adhered to form an integral unit.
- the polymer can be non-biodegradable or biodegradable, typically via hydrolysis or enzymatic cleavage.
- biodegradable refers to materials that are bioresorbable and/or degrade and/or break down by mechanical degradation upon interaction with a physiological environment into components that are metabolizable or excretable, over a period of time from minutes to three years, preferably less than one year, while maintaining the requisite structural integrity.
- the term “degrade” refers to cleavage of the polymer chain, such that the molecular weight stays approximately constant at the oligomer level and particles of polymer remain following degradation.
- Materials suitable for polymer scaffold fabrication include polylactic acid (PLA), poly-L-lactic acid (PLLA), poly-D-lactic acid (PDLA), polyglycolide, polyglycolic acid (PGA), polylactide-co-glycolide (PLGA), polydioxanone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, polyhydroxybutyrate, polyhydroxpriopionic acid, polyphosphoester, poly(alpha-hydroxy acid), polycaprolactone, polycarbonates, polyamides, polyanhydrides, polyamino acids, polyorthoesters, polyacetals, polycyanoacrylates, degradable urethanes, aliphatic polyester polyacrylates, polymethacrylate, acyl substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl flouride, polyvinyl imidazole, chlorosulphonated polyolif
- Factors including but not limited to nutrients, growth factors, inducers of differentiation or de-differentiation, products of secretion, immunomodulators, inhibitors of inflammation, regression factors, hormones, or other biologically active compounds can be incorporated into or can be provided in conjunction with the polymer scaffold.
- Agents of the invention may be supplied along with additional reagents in a kit.
- kits can include instructions for the treatment regime or assay, reagents, equipment (test tubes, reaction vessels, needles, syringes, etc.) and standards for calibrating or conducting the treatment or assay.
- the instructions provided in a kit according to the invention may be directed to suitable operational parameters in the form of a label or a separate insert.
- the kit may further comprise a standard or control information so that the test sample can be compared with the control information standard to determine if whether a consistent result is achieved.
- the present invention provides a method for restoring or enhancing spermatogenesis, comprising providing a bone marrow derived male germline stem cell, or its progenitor, to the testes of a male subject, wherein the cell engrafts into the seminiferous epithelium and differentiates into a sperm cell.
- Administration of a bone marrow derived male germline stem cell, or its progenitor, to the testes is preferably carried out by testicular injection. Direct injection into the testes advantageously circumvents the blood barrier, and provides cells to suitable locations, such as the seminiferous epithelium.
- Spermatogenesis can be further increased by contacting compositions comprising bone marrow derived male germline stem cells, or their progenitor cells, with an agent that differentiates bone marrow male germline derived stem cells or their progenitor cells into sperm cells (e.g., differentiation agents).
- an agent that differentiates bone marrow male germline derived stem cells or their progenitor cells into sperm cells e.g., differentiation agents.
- differentiation agents can be, but are not limited to, those described herein.
- spermatogenesis or the formation of spermatocytes from spermatogonia, can be regulated by numerous factors. Regulators of apoptosis, including Bax, Bcl XL family members, and caspase family members, can modulate spermatogenesis and affect male fertility (Said, T. M., et al. (2004) Hum. Reprod. Update 10: 39-51; Yan, W. et al, (2003) Mol. Endocrinol. 17: 1868). Caspases have been implicated in the pathogenesis of multiple andrological pathologies, such as, inter alia, impaired spermatogenesis, decreased sperm motility, and increased levels of sperm DNA fragmentation.
- Caspase inhibitors such as survivin and FLIP
- Caspase inhibitors can be used to regulate apoptotic events during spermatogenesis (Weikert S., (2004) Int. J. Androl. 27: 161; Giampietri, C. et al, (2003) Cell Death Differ. 10: 175).
- Bax inhibitors such as humanin, are also implicated in spermatogenic apoptosis (Guo, B. et al., (2003) Nature 423: 456).
- FGF-4 can play a critical role as a survival factor for germ cells by protecting them from apoptosis.
- Sertoli cells lactate production was induced, which is indispensable for germ cell survival.
- FGF-4 stimulation can also reduce DNA fragmentation in Sertoli cells.
- Bone morphogenetic protein (BMP) signaling pathways have also been implicated in maintenance of germ line stem cells in Drosophila (Kawase, E. et al, (2004) Development 131: 1365-75; Pellegrini, M. et al, (2003) J. Cell Sci. 116: 3363).
- BMP4 stimulation of cultured spermatogonia can induce Smad-mediated proliferation, as well as differentiation through the c-kit gene.
- BMP signals from somatic cells were shown to be essential for maintaining germline stem cells through repression of the bam expression, indicating that Bmp signals from the somatic cells maintain germline stem cells at least in part, by repressing bam expression in the testis.
- Transforming growth factor can also repress bam expression in testis. Maintenance and proliferation of germ line stem cells and their progeny depends upon the ability of these cells to transduce the activity of a somatically expressed TGF- ⁇ ligand, known in Drosophila as the BMP5/8 ortholog Glass Bottom Boat (Shivdasani, A. A. and Ingham, P. W. (2003) Curr. Biol. 13: 2065). TGF- ⁇ signaling represses the expression of bam, which is necessary and sufficient for germ cell differentiation, thereby maintaining germ line stem cells and spermatogonia in their proliferative state.
- TGF- ⁇ signaling represses the expression of bam, which is necessary and sufficient for germ cell differentiation, thereby maintaining germ line stem cells and spermatogonia in their proliferative state.
- Sphingosine-1-phosphate is also known to affect the survival and proliferation of germ line stem cells and spermatogonia.
- S1P Sphingosine-1-phosphate
- Glial-derived neurotrophic factor was found to markedly amplify germline stem cells in murine testis (Kubota, H. et al, (2004) Biol. Reprod. 71(3):722-31). Transplantation analysis demonstrated not only germline stem cells enrichment, but also differentiation from stem cells into sperm (Yomogida, K. et al, (2003) Biol. Reprod. 69: 1303).
- the present invention also provides methods for reducing bone marrow derived male germline stem cells, or their progenitor cells, in vivo, ex vivo or in vitro, comprising contacting bone marrow derived male germline stem cells or their progenitor cells with an agent that reduces cell proliferation, inhibits cell survival or promotes cell death.
- Unwanted proliferation of the cells of the invention can give rise to cancerous and pre-cancerous phenotypes (e.g., germ cell tumors, testicular cancer).
- Such methods can be used to control unwanted proliferation (e.g., cancer) or for contraceptive measures by reducing the numbers of germline stem cells, and optionally their progenitors or sperm cells.
- Agents that reduce cell proliferation include, but are not limited to, a hormone or growth factor (e.g., TGF- ⁇ ), a peptide antagonist of mitogenic hormones or growth factors (e.g., the BMP antagonists, PRDC and Gremlin), or a pharmacological or pharmaceutical compound (e.g., a cell cycle inhibitor, or an inhibitor of growth factor signaling).
- a hormone or growth factor e.g., TGF- ⁇
- a peptide antagonist of mitogenic hormones or growth factors e.g., the BMP antagonists, PRDC and Gremlin
- a pharmacological or pharmaceutical compound e.g., a cell cycle inhibitor, or an inhibitor of growth factor signaling.
- Agents that inhibit cell survival include, but are not limited to, a hormone, growth factor or cytokine (e.g., a pro-apoptotic TNF super family member such as TNF- ⁇ , FasL and TRAIL), an antagonist of pro-survival Bcl-2 family member function, a signaling molecule (e.g., a ceramide), or a pharmacological or pharmaceutical compound (e.g., an inhibitor of growth factor signaling).
- a hormone, growth factor or cytokine e.g., a pro-apoptotic TNF super family member such as TNF- ⁇ , FasL and TRAIL
- a signaling molecule e.g., a ceramide
- a pharmacological or pharmaceutical compound e.g., an inhibitor of growth factor signaling
- Agents that promote cell death include, but are not limited to, a pro-apoptotic tumor necrosis factor superfamily member (e.g., TNF- ⁇ , FasL and TRAIL), agonist of pro-apoptotic Bcl-2 family member function and ceramide.
- a pro-apoptotic tumor necrosis factor superfamily member e.g., TNF- ⁇ , FasL and TRAIL
- agonist of pro-apoptotic Bcl-2 family member function e.g., apoptotic Bcl-2 family member function
- ceramide e.g., a pro-apoptotic tumor necrosis factor superfamily member
- the invention provides methods for identifying modulators, i.e., candidate or test compounds or agents (e.g., proteins, peptides, peptidomimetics, peptoids, small molecules or other drugs) which modulate bone marrow derived germline stem cells or the progenitors thereof.
- modulators i.e., candidate or test compounds or agents (e.g., proteins, peptides, peptidomimetics, peptoids, small molecules or other drugs) which modulate bone marrow derived germline stem cells or the progenitors thereof.
- Agents thus identified can be used to modulate, for example, proliferation, survival and differentiation of a bone marrow derived germline stem cell or its progenitor e.g., in a therapeutic protocol.
- test agents of the present invention can be obtained singly or using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptide libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive; see, e.g., Zuckermann, R. N. (1994) et al., J. Med. Chem. 37:2678-85); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the ‘one-bead one-compound’ library method; and synthetic library methods using affinity chromatography selection.
- the biological library and peptoid library approaches are limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) Anticancer Drug Des. 12:145).
- Chemical compounds to be used as test agents can be obtained from commercial sources or can be synthesized from readily available starting materials using standard synthetic techniques and methodologies known to those of ordinary skill in the art.
- Synthetic chemistry transformations and protecting group methodologies useful in synthesizing the compounds identified by the methods described herein are known in the art and include, for example, those such as described in R. Larock (1989) Comprehensive Organic Transformations, VCH Publishers; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed., John Wiley and Sons (1991); L. Fieser and M.
- the compounds are organic small molecules, that is, compounds having molecular weight less than 1,000 amu, alternatively between 350-750 amu.
- the compounds are: (i) those that are non-peptidic; (ii) those having between 1 and 5, inclusive, heterocyclyl, or heteroaryl ring groups, which may bear further substituents; (iii) those in their respective pharmaceutically acceptable salt forms; or (iv) those that are peptidic.
- heterocyclyl refers to a nonaromatic 3-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring can be substituted by a substituent.
- heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring can be substituted by a substituent.
- substituted refers to a group “substituted” on an alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl group at any atom of that group.
- Suitable substituents include, without limitation, alkyl, alkenyl, alkynyl, alkoxy, halo, hydroxy, cyano, nitro, amino, SO 3 H, perfluoroalkyl, perfluoroalkoxy, methylenedioxy, ethylenedioxy, carboxyl, oxo, thioxo, imino (alkyl, aryl, aralkyl), S(O) n alkyl (where n is 0-2), S(O) n aryl (where n is 0-2), S(O) n heteroaryl (where n is 0-2), S(O) n heterocyclyl (where n is 0-2), amine (mono-, di-, alkyl,
- stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., transport, storage, assaying, therapeutic administration to a subject).
- the compounds described herein can contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.
- the compounds described herein can also be represented in multiple tautomeric forms, all of which are included herein.
- the compounds can also occur in cis-or trans-or E-or Z-double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the present invention.
- Test agents of the invention can also be peptides (e.g., growth factors, cytokines, receptor ligants).
- peptides e.g., growth factors, cytokines, receptor ligants.
- Screening methods of the invention can involve the identification of an agent that increases the proliferation or survival of bone marrow derived germline stem cells or the progenitors thereof. Such methods will typically involve contacting bone marrow derived stem or progenitor cells with a test agent in culture and quantitating the number of new bone marrow derived stem or progenitor cells produced as a result. Comparison to an untreated control can be concurrently assessed. Where an increase in the number of stem or progenitor cells is detected relative to the control, the test agent is determined to have the desired activity.
- a purified population of bone marrow derived germline stem cells or the progenitors thereof can have about 50-55%, 55-60%, 60-65% and 65-70% purity. More preferably the purity is about 70-75%, 75-80%, 80-85%; and still more preferably the purity is about 85-90%, 90-95%, and 95-100%.
- Increased amounts of bone marrow derived female germline stem cells or the progenitors thereof can also be detected by an increase in gene expression of genetic markers including an Oct-4, Dazl, Stella Vasa, Fragilis, Nobox and c-Kit.
- the level of expression can be measured in a number of ways, including, but not limited to: measuring the mRNA encoded by the genetic markers; measuring the amount of protein encoded by the genetic markers; or measuring the activity of the protein encoded by the genetic markers.
- the level of mRNA corresponding to a genetic marker can be determined both by in situ and by in vitro formats.
- the isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays.
- One diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected.
- the nucleic acid probe is sufficient to specifically hybridize under stringent conditions to mRNA or genomic DNA.
- the probe can be disposed on an address of an array, e.g., an array described below. Other suitable probes for use in the diagnostic assays are described herein.
- mRNA (or cDNA) is immobilized on a surface and contacted with the probes, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose.
- the probes are immobilized on a surface and the mRNA (or cDNA) is contacted with the probes, for example, in a two-dimensional gene chip array described below.
- a skilled artisan can adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the genetic markers described herein.
- the level of mRNA in a sample can be evaluated with nucleic acid amplification, e.g., by rtPCR (Mullis (1987) U.S. Pat. No. 4,683,202), ligase chain reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189-193), self sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al.
- amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5′ or 3′ regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between.
- amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.
- a cell or tissue sample can be prepared/processed and immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the genetic marker being analyzed.
- Screening methods of the invention can involve the identification of an agent that differentiates bone marrow derived germline stem cells, or their progenitor cells, into oocytes or sperm cells. Such methods will typically involve contacting the bone marrow derived stem or progenitor cells with a test agent in culture and quantitating the number of new oocytes or sperm cells produced as a result. Comparison to an untreated control can be concurrently assessed. Where an increase in the number of oocytes is detected relative to the control, the test agent is determined to have the desired activity.
- test agent can also be assayed using a biological sample (e.g., ovarian tissue); subsequent testing using a population of stem or progenitor cells may be conducted to distinguish the functional activity of the agent (e.g., differentiation rather then increase in proliferation or survival) where the result is ambiguous.
- a biological sample e.g., ovarian tissue
- subsequent testing using a population of stem or progenitor cells may be conducted to distinguish the functional activity of the agent (e.g., differentiation rather then increase in proliferation or survival) where the result is ambiguous.
- Increased amounts of oocytes be detected by a decrease in gene expression of bone marrow derived female germline stem or progenitor genetic markers including Oct-4, Dazl, Stella Vasa, Fragilis, Nobox or c-Kit or an increase in oocyte markers, such as HDAC6, GDF9 and ZP3.
- Bone marrow derived germline stem cells of the invention or their progenitors can be used in a variety of therapeutic applications (e.g., sperm/oocyte generation for in vivo restoration or ex vivo procedures including in vitro fertilization). Accordingly, methods of the invention relate to, among other things, the use of bone marrow derived germline stem cells, or their progenitor cells, to provide germ cells in the treatment of reproductive disorders.
- compositions comprising bone marrow derived germline stem cells or their progenitor cells can be provided directly to the reproductive organ of interest (e.g., ovary or testes).
- compositions comprising bone marrow derived germline stem cells or their progenitor cells can be provided indirectly to the reproductive organ of interest, for example, by administration into the circulatory system (e.g., to extra-ovarian circulation).
- the present invention provides methods for treating infertility in a female subject comprising providing a bone marrow derived female germline stem cell, or its progenitor, to a female subject in need thereof, wherein the cell engrafts into a tissue (preferably ovarian tissue) and differentiates into an oocyte, which can later be provided for fertilization following ovulation in the subject.
- a tissue preferably ovarian tissue
- the engrafted oocyte can be harvested from the subject and provided for in vitro fertilization or somatic cell nuclear transfer.
- the female subject in need of fertility treatment is not a subject who has undergone chemotherapy or radiotherapy.
- the present invention also provides methods for treating infertility comprising administering an agent that increases the amount of bone marrow derived female germline stem cells, or their progenitor cells, by increasing the proliferation or survival of the bone marrow derived female germline stem cells or their progenitor cells, thereby enhancing oocyte production.
- Agents can be provided directly to the reproductive organ of interest. Alternatively, agents can be provided indirectly to the reproductive organ of interest, for example, by administration into the circulatory system.
- the present invention also provides methods for repairing damaged ovarian tissue, comprising providing a bone marrow derived female germline stem cell, or its progenitor cell, to the ovarian tissue, wherein the cell engrafts into the ovarian tissue and differentiates into an oocyte.
- a bone marrow derived female germline stem cell, or its progenitor cell to the ovarian tissue, wherein the cell engrafts into the ovarian tissue and differentiates into an oocyte.
- the ovarian tissue was not damaged by chemotherapy or radiotherapy. Damage can be caused, for example, by exposure to cytotoxic factors, hormone deprivation, growth factor deprivation, cytokine deprivation, cell receptor antibodies, and the like.
- the protective agent includes, but is not limited to, S1P, Bax, or any agent that increases SDF-1 activity (i.e., SDF-1 mediated migration and homing of stem cells).
- the present invention also provides methods for restoring ovarian function in a menopausal female subject, comprising providing a bone marrow derived female germline stem cell, or its progenitor, to the subject, wherein the cell engrafts into the ovary and differentiates into an oocyte.
- the menopausal female subject can be in a stage of either peri- or post-menopause, with said menopause caused by either normal (e.g., aging) or pathological (e.g., surgery, disease, ovarian damage) processes.
- Ovarian function in a post-menopausal female can also be restored by administering an agent that increases the amount of bone marrow derived female germline stem cells or their progenitors (e.g., by increasing the number or life span of bone marrow derived female germline stem cells, as well as by increasing the differentiation of bone marrow derived female germline stem cells into oocytes).
- an agent that increases the amount of bone marrow derived female germline stem cells or their progenitors e.g., by increasing the number or life span of bone marrow derived female germline stem cells, as well as by increasing the differentiation of bone marrow derived female germline stem cells into oocytes.
- Restoration of ovarian function can relieve adverse symptoms and complications associated with menopause, including, but not limited to, somatic disorders such as osteoporosis, cardiovascular disease, somatic sexual dysfunction, hot flashes, vaginal drying, sleep disorders, depression, irritability, loss of libido, hormone imbalances, and the like, as well as cognitive disorders, such as loss of memory; emotional disorders, depression, and the like.
- somatic disorders such as osteoporosis, cardiovascular disease, somatic sexual dysfunction, hot flashes, vaginal drying, sleep disorders, depression, irritability, loss of libido, hormone imbalances, and the like
- cognitive disorders such as loss of memory; emotional disorders, depression, and the like.
- Bone marrow derived germline stem cells of the invention can be administered as previously described, and obtained by all methods known in the art.
- Bone marrow derived germline stem cells of the invention can be autologous (obtained from the subject) or heterologous (e.g., obtained from a donor).
- Heterologous cells can be provided together with immunosuppressive therapies known in the art to prevent immune rejection of the cells.
- Bone marrow derived germline stem cells of the present invention can be isolated by bone marrow aspiration. For increased yield from female donors, it may be desirable to coordinate isolation with appropriate stages of the female reproductive cycle that exhibit higher levels of female germline stem cells in the bone marrow, as described in Example 1.
- the pressure can be regulated to selectively remove bone marrow and sinusoidal blood through one of the aspiration needles, while positively forcing an intravenous solution through the other of the aspiration needles to replace the bone marrow removed from the site.
- the bone marrow and sinusoidal blood can be drawn into a chamber for mixing with another intravenous solution and thereafter forced into a collection bag.
- the heterogeneous cell population can be further purified by identification of cell-surface markers to obtain the bone marrow derived germline stem cell compositions for administration into the reproductive organ of interest.
- U.S. Pat. No. 4,486,188 describes methods of bone marrow aspiration and an apparatus in which a series of lines are directed from a chamber section to a source of intravenous solution, an aspiration needle, a second source of intravenous solution and a suitable separating or collection source.
- the chamber section is capable of simultaneously applying negative pressure to the solution lines leading from the intravenous solution sources in order to prime the lines and to purge them of any air.
- the solution lines are then closed and a positive pressure applied to redirect the intravenous solution into the donor while negative pressure is applied to withdraw the bone marrow material into a chamber for admixture with the intravenous solution, following which a positive pressure is applied to transfer the mixture of the intravenous solution and bone marrow material into the separating or collection source.
- bone marrow can be harvested during the lifetime of the subject, but a pre-menopausal harvest is recommended. Furthermore, harvest prior to illness (e.g., cancer) is desirable, and harvest prior to treatment by cytotoxic means (e.g., radiation or chemotherapy) will improve yield and is therefore also desirable.
- illness e.g., cancer
- cytotoxic means e.g., radiation or chemotherapy
- U.S. Pat. No. 5,806,529 describes a method for bone marrow transplantation from an HLA-nonmatched donor to a patient which comprises conditioning the patient under a suitable regimen followed by transplant of a very large dose of stem cells (at least about 3-fold greater than the conventional doses used in T cell-depleted bone marrow transplantation).
- the patient is conditioned under lethal or supralethal conditions for the treatment of malignant or non-malignant diseases, or under sublethal conditions for the treatment of non-malignant diseases.
- the transplant may consist of T cell-depleted bone marrow stem cells and T cell-depleted stem cell-enriched peripheral blood cells from the HLA-nonmatched donor.
- a drug e.g. a cytokine such as granulocyte colony-stimulating factor (G-CSF).
- G-CSF granulocyte colony-stimulating factor
- transplantation of bone marrow derived germline stem cells of the invention, their progenitors or their progeny should optimally be provided within about one month of the cessation of therapy.
- transplantation at later points after treatment has ceased can be done with derivable clinical outcomes.
- bone marrow derived germline stem cells and their progenitor cells, that can be used in the methods of the invention can comprise a purified sub-population of cells including, but not limited to male and female germline stem cells.
- Purified bone marrow derived germline stem cells, and their progenitor cells can be obtained by standard methods known in the art, including cell sorting by FACs. Isolated bone marrow can be sorted using flow cytometers known in the art (e.g., a BD Biosciences FACScalibur cytometer) based on cell surface expression of Sca-1 (van de Rijn et al., (1989) Proc. Natl. Acad. Sci.
- isolated bone marrow can be plated on plastic in Dulbecco's modified Eagle's medium (Fisher Scientific, Pittsburgh, Pa.) with 10% fetal bovine serum (Hyclone, Logan, Utah), penicillin, streptomycin, L-glutamine and amphotericin-B.
- the supernatants containing non-adherent cells can be removed and replaced with fresh culture medium after gentle washing.
- the cultures can then be maintained and passed once confluence is reached (e.g., for a total of about three times over the span of about 6 weeks) at which time the cultures can be terminated to collect adherent cells for analysis.
- bone marrow derived germline stem cells, their progenitors or their progeny, described herein can optionally be genetically modified, in vitro, in vivo or ex vivo, by introducing heterologous DNA or RNA or protein into the cell by a variety of recombinant methods known to those of skill in the art.
- viral transfer including the use of DNA or RNA viral vectors, such as retroviruses (including lentiviruses), Simian virus 40 (SV40), adenovirus, Sindbis virus, and bovine papillomavirus, for example;
- chemical transfer including calcium phosphate transfection and DEAE dextran transfection methods;
- membrane fusion transfer using DNA-loaded membranous vesicles such as liposomes, red blood cell ghosts, and protoplasts, for example; and (4) physical transfer techniques, such as microinjection, electroporation, or direct “naked” DNA transfer.
- the bone marrow derived germline stem cells of the invention can be genetically altered by insertion of pre-selected isolated DNA, by substitution of a segment of the cellular genome with pre-selected isolated DNA, or by deletion of or inactivation of at least a portion of the cellular genome of the cell. Deletion or inactivation of at least a portion of the cellular genome can be accomplished by a variety of means, including but not limited to genetic recombination, by antisense technology (which can include the use of peptide nucleic acids, or PNAs), or by ribozyme technology, for example.
- antisense technology which can include the use of peptide nucleic acids, or PNAs
- ribozyme technology for example.
- the altered genome may contain the genetic sequence of a selectable or screenable marker gene that is expressed so that the cell with altered genome, or its progeny, can be differentiated from cells having an unaltered genome.
- the marker may be a green, red, yellow fluorescent protein, ⁇ -galactosidase, the neomycin resistance gene, dihydrofolate reductase (DHFR), or hygromycin, but are not limited to these examples.
- the underlying defect of a pathological state is a mutation in DNA encoding a protein such as a metabolic protein.
- the polypeptide encoded by the heterologous DNA lacks a mutation associated with a pathological state.
- a pathological state is associated with a decrease in expression of a protein.
- a genetically altered bone marrow derived germline stem cell, or its progeny may contain DNA encoding such a protein under the control of a promoter that directs strong expression of the recombinant protein.
- the cell may express a gene that can be regulated by an inducible promoter or other control mechanism where conditions necessitate highly controlled regulation or timing of the expression of a protein, enzyme, or other cell product.
- the bone marrow derived germline stem cell of the invention when transplanted into a subject suffering from abnormally low expression of the protein, produce high levels of the protein to confer a therapeutic benefit.
- the bone marrow derived germline stem cell of the invention, its progenitor or its progeny can contain heterologous DNA encoding genes to be expressed, for example, in gene therapy.
- Bone marrow derived germline stem cells of the invention, their progenitors or their progeny can contain heterologous DNA encoding Atm, the gene responsible for the human disease Ataxia-telangiectasia in which fertility is disrupted.
- Providing Atm via bone marrow derived female germline stem cells, their progenitors or their progeny can further relieve defects in ovarian function.
- DNA encoding a gene product that alters the functional properties of bone marrow derived germline stem cells in the absence of any disease state is also envisioned. For example, delivery of a gene that inhibits apoptosis, or that prevents differentiation would be beneficial.
- Insertion of one or more pre-selected DNA sequences can be accomplished by homologous recombination or by viral integration into the host cell genome.
- the desired gene sequence can also be incorporated into the cell, particularly into its nucleus, using a plasmid expression vector and a nuclear localization sequence. Methods for directing polynucleotides to the nucleus have been described in the art.
- the genetic material can be introduced using promoters that will allow for the gene of interest to be positively or negatively induced using certain chemicals/drugs, to be eliminated following administration of a given drug/chemical, or can be tagged to allow induction by chemicals (including but not limited to the tamoxifen responsive mutated estrogen receptor) expression in specific cell compartments (including but not limited to the cell membrane).
- Calcium phosphate transfection can be used to introduce plasmid DNA containing a target gene or polynucleotide into isolated or cultured bone marrow derived germline stem cells or their progenitors and is a standard method of DNA transfer to those of skill in the art.
- DEAE-dextran transfection which is also known to those of skill in the art, may be preferred over calcium phosphate transfection where transient transfection is desired, as it is often more efficient.
- the cells of the present invention are isolated cells, microinjection can be particularly effective for transferring genetic material into the cells. This method is advantageous because it provides delivery of the desired genetic material directly to the nucleus, avoiding both cytoplasmic and lysosomal degradation of the injected polynucleotide. This technique has been used effectively to accomplish bone marrow derived modification in transgenic animals.
- Cells of the present invention can also be genetically modified using electroporation.
- Liposomal delivery of DNA or RNA to genetically modify the cells can be performed using cationic liposomes, which form a stable complex with the polynucleotide.
- dioleoyl phosphatidylethanolamine (DOPE) or dioleoyl phosphatidylcholine (DOPQ) can be added.
- DOPE dioleoyl phosphatidylethanolamine
- DOPQ dioleoyl phosphatidylcholine
- Commercially available reagents for liposomal transfer include Lipofectin (Life Technologies). Lipofectin, for example, is a mixture of the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N-N-N-trimethyl ammonia chloride and DOPE.
- Liposomes can carry larger pieces of DNA, can generally protect the polynucleotide from degradation, and can be targeted to specific cells or tissues. Cationic lipid-mediated gene transfer efficiency can be enhanced by incorporating purified viral or cellular envelope components, such as the purified G glycoprotein of the vesicular stomatitis virus envelope (VSV-G). Gene transfer techniques which have been shown effective for delivery of DNA into primary and established mammalian cell lines using lipopolyamine-coated DNA can be used to introduce target DNA into the bone marrow derived germline stem cells described herein.
- VSV-G vesicular stomatitis virus envelope
- Naked plasmid DNA can be injected directly into a tissue mass formed of differentiated cells from the isolated bone marrow derived germline stem cells or their progenitors. This technique has been shown to be effective in transferring plasmid DNA to skeletal muscle tissue, where expression in mouse skeletal muscle has been observed for more than 19 months following a single intramuscular injection. More rapidly dividing cells take up naked plasmid DNA more efficiently. Therefore, it is advantageous to stimulate cell division prior to treatment with plasmid DNA. Microprojectile gene transfer can also be used to transfer genes into stem cells either in vitro or in vivo. The basic procedure for microprojectile gene transfer was described by J. Wolff in Gene Therapeutics (1994), page 195. Similarly, microparticle injection techniques have been described previously, and methods are known to those of skill in the art. Signal peptides can be also attached to plasmid DNA to direct the DNA to the nucleus for more efficient expression.
- Viral vectors are used to genetically alter bone marrow derived germline stem cells of the present invention and their progeny. Viral vectors are used, as are the physical methods previously described, to deliver one or more target genes, polynucleotides, antisense molecules, or ribozyme sequences, for example, into the cells. Viral vectors and methods for using them to deliver DNA to cells are well known to those of skill in the art. Examples of viral vectors that can be used to genetically alter the cells of the present invention include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors (including lentiviral vectors), alphaviral vectors (e.g., Sindbis vectors), and herpes virus vectors.
- Peptide or protein transfection is another method that can be used to genetically alter bone marrow derived germline stem cells of the invention and their progeny.
- Peptides including, but not limited to, Pep-1 (commercially available as ChariotTM) and MPG, can quickly and efficiently transport biologically active proteins, peptides, antibodies, and nucleic acids directly into cells, with an efficiency of about 60% to about 95% (Morris, M. C. et al, (2001) Nat. Biotech. 19: 1173-1176).
- the peptide forms a non-covalent bond with the macromolecule of interest (i.e., protein, nucleic acid). The binding reaction stabilizes the protein and protects it from degradation.
- the peptide-macromolecule complex Upon delivery into the cell of interest, such as stem cells of the invention, the peptide-macromolecule complex dissociates, leaving the macromolecule biologically active and free to proceed to its target organelle. Delivery can occur in the presence of absence of serum. Uptake and delivery can occur at 4° C., which eliminates endosomal processing of incoming macromolecules. Movement of macromolecules through the endosomal pathway can modify the macromolecule upon uptake. Peptides such as Pep-1, by directly delivering a protein, antibody, or peptide of interest, bypass the transcription-translation process.
- Methods of the invention can provide oocyte reserves for use in ex vivo procedures, such as somatic cell nuclear transfer.
- Employing recombinant techniques prior to nuclear transfer will allow for the design of customized oocytes and ultimately produce embryos from which embryonic stem cells can be derived.
- genetic manipulation of donor DNA prior to nuclear transfer will result in embryos that possess the desired modification or genetic trait.
- Insertion of the donor cell or nucleus into the enucleated oocyte to form a reconstituted cell is usually by microinjection of a donor cell under the zona pellucida prior to fusion. Fusion may be induced by application of a DC electrical pulse across the contact/fusion plane (electrofusion), by exposure of the cells to fusion-promoting chemicals, such as polyethylene glycol, or by way of an inactivated virus, such as the Sendai virus.
- a reconstituted cell is typically activated by electrical and/or non-electrical means before, during, and/or after fusion of the nuclear donor and recipient oocyte.
- Activation methods include electric pulses, chemically induced shock, penetration by sperm, increasing levels of divalent cations in the oocyte, and reducing phosphorylation of cellular proteins (as by way of kinase inhibitors) in the oocyte.
- the activated reconstituted cells, or embryos, are typically cultured in medium well known to those of ordinary skill in the art and then transferred to the womb of an animal.
- embryos produced from oocytes of the invention can be genetically modified, either through manipulation of the oocyte in vitro prior to fertilization or manipulation of donor DNA prior to nuclear transfer into the enucleated oocyte, to produce embryos having a desired genetic trait.
- Oocytes produced from bone marrow derived female germline stem cells of the invention, or their progenitor cells, as described herein can also be used for methods of in vitro fertilization. Accordingly, the invention provides methods for in vitro fertilization of a female subject, comprising the steps of:
- Couples are generally first evaluated to diagnose their particular infertility problem(s). These may range from unexplained infertility of both partners to severe problems of the female (e.g., endometriosis resulting in nonpatent oviducts with irregular menstrual cycles or polycystic ovarian disease) or the male (e.g., low sperm count with morphological abnormalities, or an inability to ejaculate normally as with spinal cord lesions, retrograde ejaculation, or reversed vasectomy). The results of these evaluations also determine the specific procedure to be performed for each couple.
- Procedures often begin with the administration of a drug to down-regulate the hypothalamic/pituitary system (LHRH agonist). This process decreases serum concentrations of the gonadotropins, and developing ovarian follicles degenerate, thereby providing a set of new follicles at earlier stages of development. This permits more precise control of the maturation of these new follicles by administration of exogenous gonadotropins in the absence of influences by the hypothalamic pituitary axis. The progress of maturation and the number of growing follicles (usually four to ten stimulated per ovary) are monitored by daily observations using ultrasound and serum estradiol determinations. When the follicles attain preovulatory size (18-21 mm) and estradiol concentrations continue to rise linearly, the ovulatory response is initiated by exogenous administration of human chorionic gonadotropins (hCG).
- hCG human chorionic gonadotropins
- Oocytes can be obtained from bone marrow derived female germline stem cells, or their progenitor cells, as previously described herein.
- Bone marrow derived female germline stem cells, or the progenitor cells can be cultured in the presence of an oocyte differentiation agent which induces differentiation into oocytes.
- the differentiation agent can be supplied exogenously (e.g., added to the culture medium) or from endogenous sources during co-culture with allogenic or heterogenic ovarian tissue.
- Bone marrow derived female germline stem cells, or their progenitors can also be cultured in a tissue-engineered structure wherein the differentiation agent is either exogenously or endogenously supplied and oocytes are obtained.
- oocytes can be evaluated morphologically and transferred to a petri dish containing culture media and heat-inactivated serum.
- a semen sample is provided by the male partner and processed using a “swim up” procedure, whereby the most active, motile sperm will be obtained for insemination.
- a procedure called GIFT gamete intrafallopian transfer
- oocyte-cumulus complexes surrounded by sperm are placed directly into the oviducts by laproscopy. This procedure best simulates the normal sequences of events and permits fertilization to occur within the oviducts.
- GIFT has the highest success rate with 22% of the 3,750 patients undergoing ova retrieval in 1990 having a live delivery.
- An alternative procedure ZIFT zygote intrafallopian transfer
- Extra zygotes can be cryopreserved at this time for future transfer or for donation to couples without female gametes.
- Most patients having more serious infertility problems, however, will require an additional one to two days incubation in culture so that preembryos in the early cleavage states can be selected for transfer to the uterus.
- This IVF-UT (in vitro fertilization uterine transfer) procedure entails the transcervical transfer of several 2-6 cell (day 2) or 8-16 (day 3) preembryos to the fundus of the uterus (4-5 preembryos provides optimal success).
- SSEA1 + cells may represent germline stem cells/progenitors thereof en-route to, rather than resident in, the ovary.
- primordial germ cells primordial germ cells
- HSCs hematopoietic stem cells
- proximal epiblast the proximal epiblast
- HSCs hematopoietic stem cells
- Early HSCs colonize the aorta-gonad-mesonephric region of the developing embryo prior to migration into the fetal liver (Medvinsky and Dzierzak, (1996) Cell 86, 897-906), at roughly the equivalent time that PGCs enter the same region of the embryo to colonize the fetal gonads (McLaren, (2003) Dev. Bio. 262, 1-15); Molyneaux and Wylie, (2004) Int. J.
- ovaries, testes and bones were fixed in 4% neutral-buffered paraformaldehyde, and bones were then decalcified for 72 hr in formic acid-EDTA.
- the tissues were subsequently sectioned for immunohistochemical analysis using antibodies specific for MVH (T. Noce; Fujiwara et al., (1994) Cell Struct. Funct. 26, 131-136), HDAC6 (2162; Cell Signaling Technology, Beverly, Mass.), NOBOX (A.
- Mvh was selected as a representative endpoint to next quantitatively assess potential changes in the levels of germline marker expression in bone marrow during the female reproductive cycle.
- estrous cycle-related changes in Mvh expression in bone marrow of adult female mice were uncovered, with a 9.52-fold difference noted between estrus (nadir) and metestrus (peak) ( FIG. 2E ).
- a parallel evaluation of ovarian germ cell dynamics in the same animals revealed a striking positive correlation between the estrous cycle-related changes in bone marrow Mvh expression and primordial follicle numbers, with ovaries at metestrus containing over 800 more primordial follicles than ovaries at estrus ( FIG. 2F ).
- Mvh expression was also detected in bone marrow of adult male mice, with a level of expression slightly less than 20% of that detected in bone marrow of adult females at metestrus (Table 1).
- male bone marrow was also positive for Dazl expression, whereas Stella expression was below detectable limits.
- bone marrow samples were sorted based on cell surface stem cell markers and quantitatively analyzed the resultant cell fractions for Mvh levels. Briefly, bone marrow was isolated from adult female mice and sorted using a BD Biosciences FACScalibur cytometer based on cell surface expression of Sca-1 (van de Rijn et al., (1989) Proc. Natl. Acad. Sci.
- the supernatants containing non-adherent cells were removed and replaced with fresh culture medium after gentle washing.
- the cultures were then maintained and passed once confluence was reached for a total of three times over the span of 6 weeks, at which time the cultures were terminated to collect adherent cells for analysis.
- bone marrow was isolated from adult wild-type female mice and transplanted using standard procedures into recipient adult females sterilized by treatment with a combination of cyclophosphamide and busulphan to destroy the existing pre- and post-meiotic germ cell pools prior to BMT.
- Bone marrow was harvested from adult (6-10 weeks of age) wild-type C57BL/6 female mice on the day of transplantation, and 2-5 ⁇ 10 7 cells were injected intravenously via the tail vein into recipients using standard procedures.
- female mice received 0.5 mg anti-CD4 antibody (GK1.5) (Dialynas, D. P. et al. (1984) J. Immunol. 131, 2445-2451) and 1 mg anti-CD8 antibody (2.43) (Sarmiento, M. et al. (1980) J. Immunol.
- mice receiving BMT after combination chemotherapy possessed hundreds of oocyte-containing follicles at all stages of development, including the resting primordial stage that is most susceptible to the cytotoxic actions of these drugs ( FIGS. 4 and 5 C).
- Atm ⁇ / ⁇ mice created by targeted inactivation of the Atm gene, display many of the hallmarks of the Ataxia-telangiectasia syndrome in humans, including growth retardation, defects in T lymphocyte maturation and infertility (Bagley et al. (2004) Blood 12: 1). Atm-deficient male and female mice have been shown to be infertile due to the complete loss of the production of mature gametes, i.e., spermatozoa and oocytes (Barlow, C. et al. (1996) Cell 86: 159).
- mice were compared with ovaries from Atm gene-deficient mice.
- ovaries from Atm-null animals irrespective of postnatal age, are barren of oocytes.
- pre-meiotic germline stem cells in the postnatal mouse ovary (Johnson et al., (2004) Nature 428: 145), it was possible that pre-meiotic germline stem cells were present and capable of self-renewal, but ongoing oocyte production was impossible due to failed meiotic entry in the absence of Atm.
- Atm-deficiency results in a pool of germline stem cells that persist into adult life (day 71) but these cells cannot, as reported, produce viable oocytes due to the meiotic defect that results in gamete death when Atm is absent.
- Atm-null mouse was selected for evaluation as these animals are genetically incapable of producing oocytes. If oocytes were detected in the ovaries of Atm-null mice that received the transplants, they must be derived from the tissue transplanted (i.e., bone marrow) based on the nature of the Atm defect in the host animal. Bone marrow transplantation as performed as described above.
- Atm-null female mice were nonetheless conditioned with cyclophosphamide and busulfan (see above) to eliminate the possibility of host germ cell contribution to oocyte production following BMT.
- both the wild-type mouse and the Atm-null mouse that received exogenous, wild-type bone marrow exhibited normal oocytes within normal appearing follicles ( FIG. 8 ).
- Oocyte containing follicles were found in transplanted Atm-null females for at least 11 months after the initial BMT.
- transplanted wild-type bone marrow contains female germline stem cells which can then go on to successfully differentiate into oocytes via meiosis since these transplanted cells contain functional Atm.
- IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol. 125, 2665-2672.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/131,153 US20060010509A1 (en) | 2004-05-17 | 2005-05-17 | Methods and compositions for producing germ cells from bone marrow derived germline stem cells |
US14/308,048 US20160137978A1 (en) | 2004-05-17 | 2014-06-18 | Methods and compositions for producing germ cells from bone marrow derived germline stem cells |
US16/254,130 US20190352602A1 (en) | 2004-05-17 | 2019-01-22 | Methods and Compositions for Producing Germ Cells from Bone Marrow Derived Germline Stem Cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57222204P | 2004-05-17 | 2004-05-17 | |
US57418704P | 2004-05-24 | 2004-05-24 | |
US58664104P | 2004-07-09 | 2004-07-09 | |
US11/131,153 US20060010509A1 (en) | 2004-05-17 | 2005-05-17 | Methods and compositions for producing germ cells from bone marrow derived germline stem cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/308,048 Continuation US20160137978A1 (en) | 2004-05-17 | 2014-06-18 | Methods and compositions for producing germ cells from bone marrow derived germline stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060010509A1 true US20060010509A1 (en) | 2006-01-12 |
Family
ID=35428927
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/131,153 Abandoned US20060010509A1 (en) | 2004-05-17 | 2005-05-17 | Methods and compositions for producing germ cells from bone marrow derived germline stem cells |
US11/131,152 Abandoned US20060015961A1 (en) | 2004-05-17 | 2005-05-17 | Methods and compositions for producing germ cells from peripheral blood derived germline stem cells |
US13/006,752 Expired - Fee Related US9267111B2 (en) | 2004-05-17 | 2011-01-14 | Methods of treating female subjects in need of in vitro fertilization |
US14/308,048 Abandoned US20160137978A1 (en) | 2004-05-17 | 2014-06-18 | Methods and compositions for producing germ cells from bone marrow derived germline stem cells |
US14/990,539 Abandoned US20160362657A1 (en) | 2004-05-17 | 2016-01-07 | Methods and Compositions for Producing Germ Cells from Peripheral Blood Derived Germline Stem Cells |
US16/203,111 Abandoned US20190300852A1 (en) | 2004-05-17 | 2018-11-28 | Methods and Compositions for Producing Germ Cells from Peripheral Blood Derived Germline Stem Cells |
US16/254,130 Abandoned US20190352602A1 (en) | 2004-05-17 | 2019-01-22 | Methods and Compositions for Producing Germ Cells from Bone Marrow Derived Germline Stem Cells |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/131,152 Abandoned US20060015961A1 (en) | 2004-05-17 | 2005-05-17 | Methods and compositions for producing germ cells from peripheral blood derived germline stem cells |
US13/006,752 Expired - Fee Related US9267111B2 (en) | 2004-05-17 | 2011-01-14 | Methods of treating female subjects in need of in vitro fertilization |
US14/308,048 Abandoned US20160137978A1 (en) | 2004-05-17 | 2014-06-18 | Methods and compositions for producing germ cells from bone marrow derived germline stem cells |
US14/990,539 Abandoned US20160362657A1 (en) | 2004-05-17 | 2016-01-07 | Methods and Compositions for Producing Germ Cells from Peripheral Blood Derived Germline Stem Cells |
US16/203,111 Abandoned US20190300852A1 (en) | 2004-05-17 | 2018-11-28 | Methods and Compositions for Producing Germ Cells from Peripheral Blood Derived Germline Stem Cells |
US16/254,130 Abandoned US20190352602A1 (en) | 2004-05-17 | 2019-01-22 | Methods and Compositions for Producing Germ Cells from Bone Marrow Derived Germline Stem Cells |
Country Status (14)
Country | Link |
---|---|
US (7) | US20060010509A1 (ja) |
EP (5) | EP3498827A1 (ja) |
JP (3) | JP2008512989A (ja) |
AU (3) | AU2005245899A1 (ja) |
CA (6) | CA2566857A1 (ja) |
CY (1) | CY1116768T1 (ja) |
DK (1) | DK1765085T3 (ja) |
ES (1) | ES2547953T3 (ja) |
HK (1) | HK1221975A1 (ja) |
HU (1) | HUE027620T2 (ja) |
PL (1) | PL1765085T3 (ja) |
PT (1) | PT1765085E (ja) |
SI (1) | SI1765085T1 (ja) |
WO (3) | WO2005121321A2 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060010508A1 (en) * | 2004-05-17 | 2006-01-12 | Tilly Jonathan L | Compositions comprising female germline stem cells and methods of use thereof |
US20060015961A1 (en) * | 2004-05-17 | 2006-01-19 | Tilly Jonathan L | Methods and compositions for producing germ cells from peripheral blood derived germline stem cells |
US20080050814A1 (en) * | 2006-06-05 | 2008-02-28 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
US20080064098A1 (en) * | 2006-06-05 | 2008-03-13 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of maternal placental cells |
US20090028834A1 (en) * | 2007-07-27 | 2009-01-29 | Hal Siegel | Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance P or an analog thereof |
WO2009042127A2 (en) * | 2007-09-24 | 2009-04-02 | The General Hospital Corporation | Compositions and methods for rescuing fertility |
WO2012142500A2 (en) | 2011-04-14 | 2012-10-18 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
WO2013002880A1 (en) | 2011-06-29 | 2013-01-03 | The General Hospital Corporation | Compositions and methods for enhancing bioenergetic status in female germ cells |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007142651A1 (en) * | 2006-06-09 | 2007-12-13 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Methods and compositions for the treatment of neuropathy |
CZ299271B6 (cs) * | 2007-03-14 | 2008-06-04 | Ceská zemedelská univerzita v Praze | Použití inhibitoru histon deacetylázy pro prípravu kultivacního média na prodloužení životnosti savcích oocytu in vitro |
CN102105579A (zh) * | 2007-08-07 | 2011-06-22 | 普里梅真比奥特斯公司 | 生殖系干细胞的分离、表征和繁殖 |
EP2022847A1 (en) * | 2007-08-07 | 2009-02-11 | Irma Virant-Klun | Pluripotent stem cells, methods for their isolation and their use and culture media |
CN102250830B (zh) * | 2011-07-05 | 2013-01-16 | 西北农林科技大学 | 一种雌性生殖干细胞的体外分离及培养方法 |
US10271876B2 (en) * | 2011-11-23 | 2019-04-30 | Mezadata Medical Ip Holding Llc | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells |
CN105916977A (zh) * | 2013-10-07 | 2016-08-31 | 东北大学 | 用于使用自体细胞系统从生殖系细胞离体产生有发育能力的卵的方法和组合物 |
EP3122366A4 (en) * | 2014-03-27 | 2017-11-15 | Jonathan Lee Tilly | Methods for growth and maturation of ovarian follicles |
EP3194448A4 (en) | 2014-09-16 | 2018-03-14 | Ovascience, Inc. | Anti-vasa antibodies, and methods of production and use thereof |
AU2016324669B2 (en) * | 2015-09-17 | 2022-12-01 | Kyushu University, National University Corporation | Culture method for differentiating primordial germ cells into functionally mature oocytes |
JP6754966B2 (ja) * | 2016-02-25 | 2020-09-16 | 国立大学法人広島大学 | 始原生殖細胞の培養方法及び始原生殖細胞の培養用培地添加物 |
JP7021828B2 (ja) * | 2017-11-10 | 2022-02-17 | 一公 川島 | 卵巣由来幹細胞の減数分裂誘導法 |
CN113355386B (zh) * | 2021-06-02 | 2022-05-17 | 福建省妇幼保健院 | 一种应用三原核受精卵检测体外受精环境质量的方法 |
WO2022272042A2 (en) * | 2021-06-25 | 2022-12-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Primordial germ cells |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875854B1 (en) * | 1999-11-18 | 2005-04-05 | The Brigham And Women's Hospital, Inc. | Compositions and methods for the improved diagnosis and treatment of germ cell tumors |
US20050130302A1 (en) * | 2003-09-29 | 2005-06-16 | Reprocell Inc. | Method and composition for regulating expansion of stem cells |
US20060010508A1 (en) * | 2004-05-17 | 2006-01-12 | Tilly Jonathan L | Compositions comprising female germline stem cells and methods of use thereof |
US20060015961A1 (en) * | 2004-05-17 | 2006-01-19 | Tilly Jonathan L | Methods and compositions for producing germ cells from peripheral blood derived germline stem cells |
US20080050347A1 (en) * | 2006-08-23 | 2008-02-28 | Ichim Thomas E | Stem cell therapy for cardiac valvular dysfunction |
US20090111764A1 (en) * | 2007-10-25 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Mitochondrial selection |
US8062222B2 (en) * | 2007-06-13 | 2011-11-22 | Litron Laboratories, Ltd. | Method for measuring in vivo hematotoxicity with an emphasis on radiation exposure assessment |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854470A (en) | 1973-11-23 | 1974-12-17 | L Augspurger | Reproduction processes for cellular bodies |
IT1057895B (it) | 1975-02-17 | 1982-03-30 | Serono Lab | Gonadotropina corionica umana parzialmente desalinizzata per indurre l'ouvulazione |
US4193392A (en) | 1977-09-23 | 1980-03-18 | Barnett Gordon R | Method for removing ova from animals |
US4326505A (en) | 1980-01-07 | 1982-04-27 | Occidental Petroleum Corporation | Surgical procedure for embryo transplants on animals |
US4339434A (en) | 1981-08-17 | 1982-07-13 | Gametrics Limited | Method of increasing the incidence of female offspring |
US4845077A (en) | 1984-04-03 | 1989-07-04 | Serono Laboratories, Inc. | Method of inducing ovulation |
FR2563726B1 (fr) | 1984-05-04 | 1986-10-10 | Robert Cassou | Appareil d'insemination artificielle, notamment des carnivores |
US4642094A (en) | 1984-05-29 | 1987-02-10 | North Jr Walter L | Non-surgical embryo transfer device |
US4589402A (en) | 1984-07-26 | 1986-05-20 | Serono Laboratories, Inc. | Method of in vitro fertilization |
US4725579A (en) | 1985-02-21 | 1988-02-16 | Serono Laboratories, Inc. | Method of in vitro fertilization by a unique combination of gonadotropins |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
FR2580933B1 (fr) | 1985-04-24 | 1987-08-07 | Lenck Lucien | Capacite trans-uterine pour fecondation " in vitro in vivo " |
FR2589879B1 (fr) | 1985-11-08 | 1989-05-12 | Claude Ranoux | Conteneur pour culture anaerobie d'embryons humains |
AT387718B (de) | 1986-04-09 | 1989-03-10 | Fischl Franz H Dr | Katheder zur kuenstlichen befruchtung |
FR2608037A1 (fr) | 1986-12-10 | 1988-06-17 | Lenck Lucien | Methode d'intubation destinee a permettre la transplantation de l'oeuf ou de la matiere embryonnaire, et moyens pour sa mise en oeuvre |
FR2609885B1 (fr) | 1987-01-22 | 1989-04-14 | Cassou Robert | Instrument pour l'insemination artificielle, le transfert d'embryons ou le prelevement de liquides folliculaires chez les mammiferes |
US5538948A (en) | 1987-01-30 | 1996-07-23 | Novo Nordisk A/S | Method for treating infertility comprising administering GnRH analog, gonadotrophins, and growth hormone |
US4865589A (en) | 1987-04-22 | 1989-09-12 | Ludwig Simmet | Instrument for the transfer of materials such as sperm and embryos |
FR2614626B1 (fr) | 1987-04-30 | 1989-07-21 | Ranoux Claude | Conteneur pour fecondation des ovocytes et replacement des embryons chez l'homme et l'animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5160312A (en) | 1990-02-09 | 1992-11-03 | W. R. Grace & Co.-Conn. | Cryopreservation process for direct transfer of embryos |
US5147315A (en) | 1990-04-06 | 1992-09-15 | C. R. Bard, Inc. | Access catheter and system for use in the female reproductive system |
JPH06507565A (ja) | 1991-05-14 | 1994-09-01 | マウント シナイ スクール オヴ メディスン オヴ ザ シティー ユニバーシティー オヴ ニューヨーク | 体外受精方法および装置 |
US5627066A (en) | 1991-05-14 | 1997-05-06 | Mount Sinai School Of Medicine Of The City University Of New York | Method and apparatus for in vitro fertilization |
FR2678506B1 (fr) | 1991-07-01 | 2000-03-10 | Claude Ranoux | Procede de fecondation en cycle spontane. |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US5296375A (en) | 1992-05-01 | 1994-03-22 | Trustees Of The University Of Pennsylvania | Mesoscale sperm handling devices |
US5744366A (en) | 1992-05-01 | 1998-04-28 | Trustees Of The University Of Pennsylvania | Mesoscale devices and methods for analysis of motile cells |
US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
GB9227123D0 (en) | 1992-12-30 | 1993-02-24 | Applied Research Systems | Method |
US5563059A (en) | 1993-02-23 | 1996-10-08 | Genentech, Inc. | Use of human inhibin and human activin to increase the number of mature primate oocytes |
GB9305984D0 (en) | 1993-03-23 | 1993-05-12 | Royal Free Hosp School Med | Predictive assay |
US5360389A (en) | 1993-05-25 | 1994-11-01 | Chenette Philip E | Methods for endometrial implantation of embryos |
US5541081A (en) | 1994-03-22 | 1996-07-30 | President And Fellows Of Harvard College | Process for assessing oocyte and embryo quality |
GB9410639D0 (en) | 1994-05-27 | 1994-07-13 | Queen Mary & Westfield College | Method of improving fertilization |
JP3660026B2 (ja) | 1995-09-04 | 2005-06-15 | 扶桑薬品工業株式会社 | 体外受精用培地組成物 |
US5827174A (en) | 1995-09-26 | 1998-10-27 | Reuss, Jr.; William Alexander | Biological speciman containment and incubation pouch |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US6040340A (en) | 1996-05-07 | 2000-03-21 | Schering Aktiengesellschaft | Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors |
US5824548A (en) | 1996-05-29 | 1998-10-20 | Wisconsin Alumni Research Foundation | Method of increasing survival of cultured primate embryos in medium containing exogenous gonadotrophin releasor hormone |
US6251665B1 (en) | 1997-02-07 | 2001-06-26 | Cem Cezayirli | Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom |
CA2199663C (en) | 1997-03-11 | 2004-08-10 | Ruth Miriam Moses | In vitro maturation and fertilization of mammalian oocytes |
US5935968A (en) | 1997-03-17 | 1999-08-10 | Merck & Co., Inc. | Methods for treating polycystic ovary syndrome |
US6010448A (en) | 1997-10-17 | 2000-01-04 | Medworks Corp | Embryo transfer arrangement |
US5961444A (en) | 1997-10-17 | 1999-10-05 | Medworks Corporation | In vitro fertilization procedure using direct vision |
US6196965B1 (en) | 1998-05-21 | 2001-03-06 | Cryofacets, Inc. | Compositions methods and devices for embryo implantation for in vitro fertilization |
US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
ATE361091T1 (de) | 1999-02-24 | 2007-05-15 | Novo Nordisk As | Behandlung von unfruchtbarkeit |
BR0008468A (pt) | 1999-02-24 | 2002-02-05 | Novo Nordisk As | Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos |
AU1123301A (en) | 1999-10-27 | 2001-05-08 | General Hospital Corporation, The | Methods and compositions for enhancing developmental potential of oocytes and zygotes |
EP1233978A4 (en) | 1999-11-18 | 2003-07-23 | Brigham & Womens Hospital | COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS |
US6544166B1 (en) | 1999-11-25 | 2003-04-08 | Groendahl Christian | Treatment of human infertility |
US20020142457A1 (en) | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
US6395546B1 (en) | 2000-02-01 | 2002-05-28 | Neurogeneration, Inc. | Generation of dopaminergic neurons from human nervous system stem cells |
FR2812004B1 (fr) | 2000-07-24 | 2002-12-27 | Ccd Lab | Milieux de culture pour fecondation in vitro, ou pour la culture de follicules, cellules germinales males ou embryons |
US7527974B2 (en) | 2001-11-06 | 2009-05-05 | Shanghai Second Medical University | Embryonic stem cells derived from human somatic cell—rabbit oocyte NT units |
AUPR892501A0 (en) | 2001-11-16 | 2001-12-13 | Peter Maccallum Cancer Institute, The | Method of enhancing self renewal of stem cells and uses thereof |
US20030134422A1 (en) | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
US7390659B2 (en) | 2002-07-16 | 2008-06-24 | The Trustees Of Columbia University In The City Of New York | Methods for inducing differentiation of embryonic stem cells and uses thereof |
WO2004009758A2 (en) | 2002-07-23 | 2004-01-29 | Nanodiagnostics, Inc. | Embryonic stem cell markers and uses thereof |
WO2005007687A1 (en) | 2003-07-09 | 2005-01-27 | Dana-Farber Cancer Institute, Inc | Compositions and methods for modulating ovarian follicular initiation |
EP2787073B1 (en) | 2011-04-14 | 2019-03-20 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
-
2005
- 2005-05-17 SI SI200532007T patent/SI1765085T1/sl unknown
- 2005-05-17 JP JP2007527370A patent/JP2008512989A/ja not_active Withdrawn
- 2005-05-17 EP EP18207405.4A patent/EP3498827A1/en not_active Withdrawn
- 2005-05-17 PT PT57826976T patent/PT1765085E/pt unknown
- 2005-05-17 DK DK05782697.6T patent/DK1765085T3/en active
- 2005-05-17 JP JP2007527371A patent/JP2008512990A/ja not_active Withdrawn
- 2005-05-17 EP EP05779982A patent/EP1765985A4/en not_active Withdrawn
- 2005-05-17 AU AU2005245899A patent/AU2005245899A1/en not_active Abandoned
- 2005-05-17 EP EP15168666.4A patent/EP2987855B1/en not_active Not-in-force
- 2005-05-17 CA CA002566857A patent/CA2566857A1/en not_active Abandoned
- 2005-05-17 WO PCT/US2005/017221 patent/WO2005121321A2/en active Application Filing
- 2005-05-17 US US11/131,153 patent/US20060010509A1/en not_active Abandoned
- 2005-05-17 EP EP05782697.6A patent/EP1765085B1/en active Active
- 2005-05-17 WO PCT/US2005/017233 patent/WO2005113752A2/en active Search and Examination
- 2005-05-17 JP JP2007527367A patent/JP2007537754A/ja not_active Withdrawn
- 2005-05-17 CA CA002569031A patent/CA2569031A1/en not_active Abandoned
- 2005-05-17 AU AU2005257839A patent/AU2005257839A1/en not_active Abandoned
- 2005-05-17 CA CA2841716A patent/CA2841716C/en not_active Expired - Fee Related
- 2005-05-17 EP EP05783644A patent/EP1765983A4/en not_active Withdrawn
- 2005-05-17 WO PCT/US2005/017234 patent/WO2006001938A2/en active Application Filing
- 2005-05-17 CA CA2897658A patent/CA2897658A1/en not_active Abandoned
- 2005-05-17 PL PL05782697T patent/PL1765085T3/pl unknown
- 2005-05-17 CA CA2566851A patent/CA2566851C/en not_active Expired - Fee Related
- 2005-05-17 AU AU2005252636A patent/AU2005252636A1/en not_active Abandoned
- 2005-05-17 HU HUE05782697A patent/HUE027620T2/en unknown
- 2005-05-17 US US11/131,152 patent/US20060015961A1/en not_active Abandoned
- 2005-05-17 CA CA3009909A patent/CA3009909A1/en not_active Abandoned
- 2005-05-17 ES ES05782697.6T patent/ES2547953T3/es active Active
-
2011
- 2011-01-14 US US13/006,752 patent/US9267111B2/en not_active Expired - Fee Related
-
2014
- 2014-06-18 US US14/308,048 patent/US20160137978A1/en not_active Abandoned
-
2015
- 2015-10-06 CY CY20151100889T patent/CY1116768T1/el unknown
-
2016
- 2016-01-07 US US14/990,539 patent/US20160362657A1/en not_active Abandoned
- 2016-08-24 HK HK16110078.6A patent/HK1221975A1/zh not_active IP Right Cessation
-
2018
- 2018-11-28 US US16/203,111 patent/US20190300852A1/en not_active Abandoned
-
2019
- 2019-01-22 US US16/254,130 patent/US20190352602A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875854B1 (en) * | 1999-11-18 | 2005-04-05 | The Brigham And Women's Hospital, Inc. | Compositions and methods for the improved diagnosis and treatment of germ cell tumors |
US20050130302A1 (en) * | 2003-09-29 | 2005-06-16 | Reprocell Inc. | Method and composition for regulating expansion of stem cells |
US20060010508A1 (en) * | 2004-05-17 | 2006-01-12 | Tilly Jonathan L | Compositions comprising female germline stem cells and methods of use thereof |
US20060015961A1 (en) * | 2004-05-17 | 2006-01-19 | Tilly Jonathan L | Methods and compositions for producing germ cells from peripheral blood derived germline stem cells |
US7955846B2 (en) * | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
US20080050347A1 (en) * | 2006-08-23 | 2008-02-28 | Ichim Thomas E | Stem cell therapy for cardiac valvular dysfunction |
US8062222B2 (en) * | 2007-06-13 | 2011-11-22 | Litron Laboratories, Ltd. | Method for measuring in vivo hematotoxicity with an emphasis on radiation exposure assessment |
US20090111764A1 (en) * | 2007-10-25 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Mitochondrial selection |
Non-Patent Citations (1)
Title |
---|
Ghadami et al PLos One 2012;7(3):e32462,1-7. * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8652840B2 (en) | 2004-05-17 | 2014-02-18 | The General Hospital Corporation | Method for obtaining female germline stem cells and uses thereof |
US20060015961A1 (en) * | 2004-05-17 | 2006-01-19 | Tilly Jonathan L | Methods and compositions for producing germ cells from peripheral blood derived germline stem cells |
US20060010508A1 (en) * | 2004-05-17 | 2006-01-12 | Tilly Jonathan L | Compositions comprising female germline stem cells and methods of use thereof |
US9962411B2 (en) | 2004-05-17 | 2018-05-08 | The General Hospital Corporation | Isolated populations of female germline stem cells and cell preparations and compositions thereof |
US7955846B2 (en) | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
US9267111B2 (en) | 2004-05-17 | 2016-02-23 | The General Hospital Corporation | Methods of treating female subjects in need of in vitro fertilization |
US20080050814A1 (en) * | 2006-06-05 | 2008-02-28 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
US20080064098A1 (en) * | 2006-06-05 | 2008-03-13 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of maternal placental cells |
US20090028834A1 (en) * | 2007-07-27 | 2009-01-29 | Hal Siegel | Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance P or an analog thereof |
WO2009042127A2 (en) * | 2007-09-24 | 2009-04-02 | The General Hospital Corporation | Compositions and methods for rescuing fertility |
WO2009042127A3 (en) * | 2007-09-24 | 2009-05-14 | Gen Hospital Corp | Compositions and methods for rescuing fertility |
US8642329B2 (en) | 2011-04-14 | 2014-02-04 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
US8647869B2 (en) | 2011-04-14 | 2014-02-11 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
EP2787073A1 (en) | 2011-04-14 | 2014-10-08 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
US9150830B2 (en) | 2011-04-14 | 2015-10-06 | The General Hospital Corporation | Compositions for autologous ovarian oogonial stem cell mitochondrial energy transfer |
WO2012142500A2 (en) | 2011-04-14 | 2012-10-18 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
EP3498826A1 (en) | 2011-04-14 | 2019-06-19 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
WO2013002880A1 (en) | 2011-06-29 | 2013-01-03 | The General Hospital Corporation | Compositions and methods for enhancing bioenergetic status in female germ cells |
US9845482B2 (en) | 2011-06-29 | 2017-12-19 | The General Hospital Corporation | Compositions and methods for enhancing bioenergetic status in female germ cells |
EP3495470A1 (en) | 2011-06-29 | 2019-06-12 | The General Hospital Corporation | In vivo methods for enhancing bioenergetic status in female germ cells |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190352602A1 (en) | Methods and Compositions for Producing Germ Cells from Bone Marrow Derived Germline Stem Cells | |
US20180200305A1 (en) | Isolated Populations of Female Germline Stem Cells and Cell Preparations and Compositions Thereof | |
JP2021126129A (ja) | 疾患を処置するための遺伝子改変された細胞、組織および臓器 | |
JP2002511732A (ja) | トランスジェニック動物を発生させるための組成物および方法 | |
Class et al. | Patent application title: METHODS AND COMPOSITIONS FOR PRODUCING GERM CELLS FROM BONE MARROW DERIVED GERMLINE STEM CELLS Inventors: Jonathan L. Tilly (Windham, NH, US) Joshua Johnson (New Haven, CT, US) | |
Class et al. | Patent application title: Isolated populations of female germline stem cells and cell preparations and compositions thereof Inventors: Jonathan Lee Tilly (Windham, NH, US) Joshua Johnson (New Haven, CT, US) | |
Class et al. | Patent application title: COMPOSITIONS COMPRISING FEMALE GERMLINE STEM CELLS AND METHODS OF USE THEREOF Inventors: Jonathan Lee Tilly (Windham, NH, US) Joshua Johnson (New Haven, CT, US) Assignees: The General Hospital Corporation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENERAL HOSPITAL CORPORATION, THE, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TILLY, JONATHAN L.;JOHNSON, JOSHUA;REEL/FRAME:017014/0238;SIGNING DATES FROM 20050818 TO 20050819 |
|
AS | Assignment |
Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TILLY, JONATHAN L.;JOHNSON, JOSHUA;SIGNING DATES FROM 20120315 TO 20120424;REEL/FRAME:028168/0501 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |